Translational Models
Translational Model Navigator
Identify the right preclinical and translational models for your program. Filter by modality, therapeutic area, study type, or development stage to build a model strategy that supports your IND submission.
Showing 68 of 68 models
Bleomycin-Induced Pulmonary Fibrosis Mouse Model
Preclinical efficacy testing of antifibrotic therapeutics for IPF and other fibrotic lung diseases, including assessment of collagen deposition, lung function, and histopathological endpoints.
Description
Pulmonary fibrosis model induced by intratracheal or oropharyngeal instillation of bleomycin sulfate in C57BL/6 mice. Develops inflammatory phase (days 0-7), transitional phase (days 7-14), and established fibrosis (days 14-28+) with collagen deposition, alveolar architecture disruption, and impaired lung function. The most widely used IPF model — both FDA-approved antifibrotics (nintedanib and pirfenidone) were validated in this model.
Advantages
- Most widely used IPF model — nintedanib and pirfenidone both validated in bleomycin-induced fibrosis
- C57BL/6 strain is a robust responder with reproducible fibrosis development
- Well-characterized temporal disease progression enables intervention at inflammatory or fibrotic stages
- Multiple quantitative endpoints: Ashcroft score, hydroxyproline content, micro-CT, lung function testing
- Supports therapeutic vs. prophylactic dosing paradigms to differentiate anti-inflammatory from antifibrotic effects
Limitations
- Self-resolving model — fibrosis peaks at 21-28 days and partially resolves, unlike progressive human IPF
- Inflammatory phase is prominent and may drive fibrosis through mechanisms not central to human IPF
- Single intratracheal dose creates uneven lung distribution — Microsprayer improves homogeneity
- Does not capture the chronic progressive nature or honeycombing pattern of end-stage human IPF
- Variable mortality (10-30%) depending on bleomycin dose and administration technique
Regulatory Notes
Bleomycin-induced pulmonary fibrosis is the most commonly accepted IPF efficacy model by FDA and EMA. FDA expects antifibrotic efficacy data with histopathological scoring (Ashcroft score) and quantitative collagen endpoints (hydroxyproline) in IND pharmacology sections. Therapeutic dosing paradigm (treatment initiated after fibrosis establishment at day 10-14) is preferred over prophylactic dosing for clinical relevance.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Bolder BioPATH (Inotiv) · Crown Bioscience
Collagen-Induced Arthritis (CIA) Mouse Model
Preclinical efficacy testing of anti-inflammatory, anti-TNF, anti-IL-6, JAK inhibitor, and other immunomodulatory therapeutics targeting rheumatoid arthritis and autoimmune joint disease.
Description
Autoimmune arthritis model induced by immunization with type II collagen in Complete Freund's Adjuvant (CFA). DBA/1 mice develop polyarthritis within 21-35 days post-immunization with synovial inflammation, pannus formation, cartilage destruction, and bone erosion closely resembling human rheumatoid arthritis. The gold standard RA efficacy model — all approved anti-TNF agents (infliximab, etanercept, adalimumab) and JAK inhibitors (tofacitinib, baricitinib) were validated in this model.
Advantages
- Gold standard RA model — all approved anti-TNF and JAK inhibitor therapies validated in CIA
- Well-characterized clinical scoring system (paw swelling, arthritis index) enables quantitative dose-response
- T-cell and B-cell mediated autoimmune pathology closely mirrors human RA immunopathogenesis
- Reproducible disease onset and progression in DBA/1 mice with extensive historical control data
- Supports histopathological endpoints (synovitis, cartilage erosion, bone destruction) translatable to clinical imaging
Limitations
- Strain-restricted — requires MHC class II haplotype H-2q (DBA/1) for robust induction
- Self-limiting disease course (peaks at 5-6 weeks) — does not model chronic progressive RA
- Requires CFA containing heat-killed Mycobacterium tuberculosis, which drives non-specific inflammation
- Onset variability between animals requires larger group sizes (n=10-15) for adequate statistical power
- Mouse-specific agents required unless the therapeutic cross-reacts with murine targets
Regulatory Notes
CIA is the most widely accepted preclinical RA efficacy model by FDA and EMA. Data from CIA studies is routinely included in IND pharmacology sections (Module 2.6.2, Module 4.2.1) for anti-inflammatory biologics and small molecules targeting autoimmune arthritis. FDA expects a scientifically justified rationale for model selection and dose-response data with histopathological confirmation.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Hooke Laboratories · Charles River Laboratories · Bolder BioPATH (Inotiv)
Common Marmoset (Callithrix jacchus)
Nonclinical toxicology and pharmacology for biologics where marmoset target cross-reactivity is confirmed, CNS and rare disease programs, and situations where cynomolgus supply is constrained or compound availability is limited.
Description
Small New World primate (350-450 g body weight) increasingly used as an alternative to cynomolgus macaque for nonclinical toxicology and pharmacology of biologics. Purpose-bred, early sexual maturity, and high reproductive rate. Accepted by regulatory agencies for IND, NDA, and MAA submissions. Growing use driven by cynomolgus supply constraints (post-2020) and lower compound requirements due to small body size.
Advantages
- Small body size (350-450 g) dramatically reduces test article requirements compared to cynomolgus (3-5 kg)
- Purpose-bred colonies with early sexual maturity and high reproductive rate — faster colony expansion
- Regulatory acceptance for IND, NDA, and MAA registrations as a non-rodent species
- One of the few species capable of showing drug-induced torsades de pointes — valuable for cardiac safety
- Growing cynomolgus supply constraints make marmoset an increasingly practical alternative
Limitations
- Limited reagent and antibody cross-reactivity compared to cynomolgus — immunoassay development needed
- Smaller blood volume (5-7 mL total) constrains serial sampling — microsampling techniques often required
- New World primate — phylogenetically more distant from human than Old World macaques
- Fewer CROs offer marmoset studies compared to cynomolgus — capacity constraints
- Historical control database smaller than cynomolgus for most toxicology endpoints
Regulatory Notes
FDA, EMA, and PMDA accept marmoset as a non-rodent species for nonclinical toxicology per ICH S6(R1) and ICH M3(R2) when scientifically justified. Marmoset data has been accepted in IND, CTX, NDA, and MAA registrations. Species selection requires demonstration of target cross-reactivity and scientific justification per ICH S6(R1). FDA reviewers expect tissue cross-reactivity data and clear rationale for choosing marmoset over cynomolgus.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
CLEA Japan · SNBL (Shin Nippon Biomedical Laboratories) · Charles River Laboratories
Cotton Rat (Sigmodon hispidus)
Preclinical efficacy and dose-finding for RSV therapeutics and vaccines, respiratory virus immunoprophylaxis evaluation, and maternal immunization studies for neonatal protection.
Description
Inbred cotton rat (Sigmodon hispidus) naturally permissive to human respiratory syncytial virus (RSV) without viral adaptation. The gold standard small animal model for RSV drug and vaccine development — accurately predicted both efficacy and dose of palivizumab (Synagis). Also validated for influenza, human parainfluenza virus (hPIV), human metapneumovirus (hMPV), and measles virus.
Advantages
- Gold standard RSV model — accurately predicted palivizumab efficacy and clinical dose
- Naturally permissive to human RSV strains without viral adaptation, preserving clinical relevance
- Models maternally transmitted immunity and vaccine-enhanced disease (FI-RSV), critical safety considerations
- Validated for multiple respiratory viruses: RSV, influenza, hPIV, hMPV, measles
- Supports both prophylactic (passive immunization) and therapeutic intervention studies
Limitations
- Very limited commercial availability — primarily sourced from Sigmovir Biosystems inbred colony
- Smaller reagent and antibody toolbox compared to standard mouse strains
- Limited genetic tools — no transgenic or knockout cotton rat lines routinely available
- Higher per-animal cost than standard mice due to specialized breeding and limited supply
- Semi-permissive for RSV — viral replication is lower than in human airways
Regulatory Notes
Cotton rat RSV data is standard in IND submissions for RSV therapeutics and vaccines. FDA has historically relied on cotton rat efficacy data for RSV monoclonal antibody development (palivizumab, nirsevimab). The model is accepted for demonstrating RSV neutralization, viral load reduction, and pulmonary pathology prevention. FDA expects cotton rat data as part of the preclinical efficacy package for RSV programs.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Sigmovir Biosystems · BIOQUAL
Dog (Beagle)
GLP repeat-dose toxicology (non-rodent species), cardiovascular safety pharmacology (hERG follow-up in vivo telemetry), oral bioavailability assessment, and dose-limiting toxicity identification.
Description
Purpose-bred Beagle dogs are the standard non-rodent species for repeat-dose toxicology, cardiovascular safety pharmacology (telemetry), and oral bioavailability studies. The default non-rodent for small molecules and many biologics.
Advantages
- Extensive historical control database for toxicology endpoints across all organ systems
- Gold standard for cardiovascular safety pharmacology (jacketed telemetry, ECG parameters)
- Oral absorption and bioavailability often predictive of human for many compound classes
- Large enough for serial blood sampling, imaging, and repeated dosing procedures
- Regulatory agencies have highest confidence in dog as non-rodent for small molecules
Limitations
- Highest ethical scrutiny of standard toxicology species — strong 3Rs pressure
- Emetic reflex present (unlike rodents) — can limit oral dosing for emetogenic compounds
- Bile acid composition and gastrointestinal transit differences from humans may limit prediction of human oral absorption and hepatobiliary effects
- Dog-specific toxicities (e.g., testicular toxicity with kinase inhibitors) may not be human-relevant
- High per-study cost ($350K-800K for a 4-week GLP study) and long timelines
Regulatory Notes
Standard non-rodent species for general toxicology per ICH M3(R2) and S4. FDA expects Beagle dog as the default non-rodent unless scientifically justified otherwise. Cardiovascular telemetry in dog is the gold standard for ICH S7B QT prolongation assessment. Dog + rat is the standard two-species toxicology package for small molecules.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Labcorp Drug Development · SNBL (Shin Nippon Biomedical Laboratories)
DSS-Induced Colitis Mouse Model
Preclinical efficacy testing of anti-inflammatory and mucosal healing therapeutics for ulcerative colitis and IBD, and evaluation of epithelial barrier protection and innate immune modulation.
Description
Inflammatory bowel disease model induced by administration of dextran sulfate sodium (DSS, 40-50 kDa) in drinking water. Produces acute colitis with bloody diarrhea, weight loss, colonic inflammation, epithelial erosion, and crypt damage resembling human ulcerative colitis. C57BL/6 develops more severe chronic disease; BALB/c recovers more readily. Cyclic DSS administration produces chronic relapsing colitis.
Advantages
- Most widely used and simplest IBD model — no immunization, surgical, or genetic manipulation required
- Pathology resembles human ulcerative colitis with epithelial erosion, crypt damage, and inflammatory infiltrate
- Acute (single cycle) and chronic (cyclic dosing) protocols available to model disease stages
- Multiple quantitative endpoints: DAI score, colon length, histopathology, MPO, cytokines
- Cost-effective with reproducible disease induction and well-characterized pharmacological controls
Limitations
- Primarily innate immune-driven — does not fully capture adaptive immune pathology of human IBD
- Dose sensitivity varies by DSS lot, molecular weight, vendor, and mouse substrain — standardization critical
- C57BL/6 develops chronic disease after DSS removal; BALB/c recovers — strain selection affects study design
- Does not model transmural inflammation characteristic of Crohn's disease
- Colonic-only involvement — does not capture small intestinal pathology seen in Crohn's disease
Regulatory Notes
DSS colitis is the most widely accepted preclinical IBD efficacy model by FDA and EMA. Routinely included in IND pharmacology sections for ulcerative colitis and IBD therapeutics. FDA expects dose-response data with histopathological confirmation of colonic inflammation and mucosal damage. Disease Activity Index (DAI) scoring and colon length measurement are standard endpoints.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Crown Bioscience · Hooke Laboratories
Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model
Preclinical efficacy testing of immunomodulatory, anti-inflammatory, and remyelinating therapies for multiple sclerosis and neuroinflammatory conditions.
Description
Autoimmune demyelination model induced by immunization with myelin peptides (MOG35-55 in C57BL/6, PLP139-151 in SJL) in CFA with pertussis toxin. Develops ascending flaccid paralysis from autoimmune T-cell-mediated CNS inflammation and demyelination. MOG35-55/C57BL/6 produces chronic monophasic EAE; PLP/SJL produces relapsing-remitting EAE. The standard efficacy model for multiple sclerosis drug development.
Advantages
- Most widely used and accepted MS preclinical efficacy model — decades of validation data
- MOG35-55/C57BL/6 is highly reproducible with well-characterized clinical scoring (0-5 scale)
- Disease onset at 9-14 days with peak disease 3-5 days later — efficient study timelines
- Relapsing-remitting (PLP/SJL) and chronic progressive (MOG/C57BL/6) variants model different MS subtypes
- Supports multiple endpoints: clinical score, histopathology (demyelination, infiltration), MRI, and biomarkers
Limitations
- Immunization-driven model — does not capture the spontaneous autoimmune initiation seen in MS
- CFA/pertussis toxin adjuvants drive non-specific inflammation that may confound immunomodulatory agent testing
- Remyelination occurs spontaneously in rodents — may overestimate remyelinating drug efficacy
- Predominantly T-cell-mediated — may underestimate B-cell-mediated pathology important in human MS
- Species-specific therapeutic targets require surrogate or cross-reactive agents
Regulatory Notes
EAE is the standard preclinical MS efficacy model accepted by FDA and EMA. Data from EAE studies is routinely included in IND pharmacology sections for MS therapeutics. FDA expects EAE data with dose-response, clinical scoring, and histopathological confirmation of CNS demyelination and inflammation for immunomodulatory agents targeting MS.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Hooke Laboratories · Charles River Laboratories · MD Biosciences
Ferret (Mustela putorius furo)
Respiratory virus infection models, vaccine efficacy/immunogenicity, and emesis assessment for compounds with potential GI toxicity.
Description
Standard model for respiratory infection (influenza, SARS-CoV-2), vaccine development, and emesis studies. Ferrets are uniquely susceptible to human respiratory viruses and possess a functional vomiting reflex absent in rodents.
Advantages
- Gold standard for influenza and respiratory virus research
- Susceptible to human respiratory viruses without adaptation
- Functional emesis reflex (absent in rodents)
- Similar respiratory tract anatomy to humans
- Well-established for vaccine development
Limitations
- Limited genetic tools compared to mouse
- Smaller reagent/antibody availability
- Specialized housing requirements
- Higher per-animal cost than rodents
- Limited historical toxicology database compared to rat/dog
Regulatory Notes
Accepted for respiratory infection efficacy studies and vaccine development programs. Standard model for influenza vaccine licensure. Also used for emesis assessment per ICH S7A when evaluating compounds with emetic potential.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Triple F Farms · Marshall BioResources · BIOQUAL
Genetically Engineered Mouse Model (GEMM)
Modeling tumor development and progression in a physiologically relevant immune-competent setting, testing early intervention strategies, and evaluating agents targeting the tumor microenvironment.
Description
Mice carrying oncogene activation and/or tumor suppressor loss engineered to develop spontaneous tumors in an immune-competent setting (e.g., KPC for pancreatic cancer, MMTV-PyMT for breast, APCmin for colorectal). Highest translational fidelity for tumor biology.
Advantages
- Spontaneous tumor development in native tissue with authentic microenvironment
- Immune-competent host enables study of tumor-immune interactions
- Recapitulates tumor initiation, progression, and metastasis stages
- Gold standard translational relevance — highest fidelity to human tumor biology
- Supports prevention and early-intervention study designs not possible with transplant models
Limitations
- Long latency to tumor development (8-52 weeks depending on model) reduces throughput
- Variable tumor onset requires large cohorts and imaging-based enrollment
- Very expensive due to breeding colony maintenance and long study timelines
- Limited to mouse-specific agents or cross-reactive therapeutics
- Complex genetics can make model characterization and reproducibility challenging
Regulatory Notes
FDA considers GEMM data among the most persuasive nonclinical efficacy evidence for oncology INDs (ICH S9). Particularly valued for novel targets where CDX/PDX data is insufficient. GEMM data can strengthen the scientific rationale in Module 2.6.2, especially when combined with biomarker and mechanism-of-action data.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
The Jackson Laboratory · Taconic Biosciences · NCI Mouse Repository
Guinea Pig
Dermal sensitization testing (Buehler, Maximization test), auditory safety assessment, complement-mediated reaction evaluation, and respiratory infection models.
Description
Used primarily for skin sensitization testing (traditional sensitization standard, now supplemented by murine LLNA and in vitro Defined Approaches), auditory toxicology, anaphylaxis assessment, and certain respiratory and infectious disease models. Also used for complement activation studies.
Advantages
- Gold standard for dermal sensitization testing (Magnusson-Kligman, Buehler)
- Complement system closer to human than mouse or rat — useful for CARPA risk assessment
- Well-established auditory toxicology model (aminoglycoside ototoxicity)
- Robust respiratory infection models (tuberculosis, influenza)
- Vitamin C-dependent metabolism (like humans) — relevant for certain metabolic studies
Limitations
- Limited genetic tools and genetically modified models available
- Smaller reagent ecosystem than mouse or rat
- Not a standard species for general toxicology or PK — limited historical control data
- Sensitive to antibiotic-induced GI disruption
- Dermal sensitization testing increasingly replaced by in vitro NAMs (DPRA, h-CLAT, KeratinoSens)
Regulatory Notes
FDA and EMA accept guinea pig data for dermal sensitization per OECD TG 406, though the in vitro Defined Approach (DA, OECD GL 497) is now preferred. Guinea pig remains accepted for complement activation-related pseudo-allergy (CARPA) assessment of nanomedicines and lipid nanoparticle formulations.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Envigo (Inotiv)
Humanized Mouse — Immune System (NSG, huPBMC, huCD34+)
Immuno-oncology efficacy (checkpoint inhibitors, bispecifics, CAR-T), immunogenicity assessment of biologics, and GvHD/autoimmunity modeling.
Description
Immunodeficient mice (NSG, NOG, or BRGS) reconstituted with human immune cells (huPBMC for short-term, huCD34+ HSC for long-term engraftment). Enables evaluation of human immune-mediated efficacy and safety in vivo.
Advantages
- Functional human immune system enables testing of human-specific immunotherapies
- huCD34+ models develop T, B, NK, dendritic cells, and myeloid lineages
- Critical for biologics that require human immune context (anti-PD-1, bispecifics)
- Can combine with CDX or PDX tumors for immuno-oncology models
- Increasingly accepted by FDA for IO proof-of-concept per ICH S9
Limitations
- huPBMC models develop GvHD within 4-6 weeks, limiting study duration
- Incomplete myeloid reconstitution in most humanized platforms
- Variable engraftment levels between cohorts and donors require QC gating
- Very expensive compared to standard mouse models ($400-800+ per animal)
- Does not fully recapitulate human tissue-resident immune populations
Regulatory Notes
FDA and EMA accept humanized immune mouse models for proof-of-concept efficacy of immuno-oncology agents (ICH S9, ICH S6(R1)). Particularly valued when the therapeutic is human-specific and no pharmacologically relevant animal model exists. FDA reviewers expect documentation of engraftment levels and donor characterization.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
The Jackson Laboratory (NSG) · Champions Oncology · Crown Bioscience
Humanized Mouse — Target-Specific (Human Target Knock-In)
Pharmacology and efficacy testing of monoclonal antibodies, bispecifics, and other biologics that do not cross-react with mouse orthologs.
Description
Mice engineered to express a human version of the drug target (e.g., human PD-1, human CD20, human FcRn) in place of the mouse ortholog. Enables pharmacology testing of human-specific biologics in an immune-competent host.
Advantages
- Enables testing of human-specific biologics in an immune-competent animal
- Intact immune system allows physiological immune context (vs. humanized immune models)
- Supports PK studies with human FcRn knock-in for better IgG half-life prediction
- Multiple targets available commercially (PD-1, PD-L1, CD20, CTLA-4, HER2, TIGIT)
- Can combine target knock-in with syngeneic tumor models for IO studies
Limitations
- Limited to targets for which knock-in models exist or can be generated
- Custom model generation takes 6-12 months and costs $50K-150K+
- Mouse biology around the target may differ from human (signaling, expression patterns)
- Not suitable for safety pharmacology core battery (non-standard strain)
- Breeding requirements can create timeline bottlenecks
Regulatory Notes
FDA accepts human target knock-in models as pharmacologically relevant species for biologics per ICH S6(R1). These models are especially valued when the drug candidate is highly species-specific and no relevant NHP cross-reactivity exists. FDA expects clear justification of the model's relevance to human target biology.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
genOway · Taconic Biosciences · The Jackson Laboratory
Intrathecal Delivery Model (NHP, Rodent)
Biodistribution, PK/PD, and toxicology assessment for intrathecally delivered CNS therapeutics including ASOs, AAV gene therapies, and enzyme replacement therapies.
Description
In vivo models for intrathecal (IT) drug delivery to the CNS, including large animal models with implanted IT catheters for repeat-dose studies. Critical for ASO, gene therapy, and enzyme replacement therapy programs targeting the CNS.
Advantages
- NHP IT delivery closely mimics human CSF pharmacokinetics
- Enables CNS biodistribution assessment with spinal cord and brain sampling
- Well-characterized surgical procedure for catheter implantation in NHP
- FDA expects IT PK and biodistribution data in a large animal for CNS programs
Limitations
- NHP IT studies are expensive ($500K-2M+) and require specialized surgical capabilities
- Mouse IT injection is technically challenging with high variability
- Catheter-related complications (infections, obstructions) can confound results
- CSF volume differences between species complicate dose scaling to humans
Regulatory Notes
FDA expects IT biodistribution and toxicology data in a pharmacologically relevant large animal species (typically NHP) for all intrathecally delivered CNS therapeutics. The 2020 FDA Gene Therapy Guidance addresses IT delivery specifically. CSF PK sampling in NHP is standard for IT ASO programs per FDA Antisense Oligonucleotide Drug Products guidance.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Labcorp Drug Development · SNBL (Shin Nippon Biomedical Laboratories)
Knockout Mouse
Target validation, loss-of-function disease modeling (e.g., lysosomal storage disorders, metabolic diseases), and understanding on-target safety liabilities of gene-targeted therapeutics.
Description
Mice with targeted gene disruption (conventional or conditional) to model loss-of-function diseases, validate therapeutic targets, or study gene function. Includes Cre-lox conditional knockouts for tissue-specific or temporal gene deletion.
Advantages
- Clean genetic background for unambiguous target validation
- Large existing catalog from IMPC and KOMP — over 9,000 genes phenotyped
- Conditional knockouts enable tissue-specific and temporal control
- Well-suited for gene replacement therapy efficacy (complete null phenotype)
- Valuable for understanding on-target toxicity risk of pharmacological inhibitors
Limitations
- Complete null may not model hypomorphic human mutations accurately
- Embryonic lethality in ~30% of global knockouts limits utility
- Compensatory mechanisms during development may mask adult phenotypes
- Conditional systems (Cre-lox) can have leaky or incomplete recombination
- May require extensive backcrossing to achieve clean genetic background
Regulatory Notes
Accepted by FDA for pharmacology and target validation studies. Knockout models are especially valued in gene therapy INDs where the null phenotype demonstrates the disease and restoration of gene expression demonstrates efficacy. IMPC-catalogued models carry strong scientific justification.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
The Jackson Laboratory · MMRRC/KOMP · Taconic Biosciences
Laser-Induced CNV Model (Wet AMD)
Preclinical efficacy testing of anti-VEGF agents, antiangiogenic therapies, gene therapy approaches for sustained anti-VEGF expression, and novel intravitreal drug delivery systems for wet AMD.
Description
Choroidal neovascularization (CNV) model induced by laser photocoagulation to rupture Bruch's membrane, triggering subretinal neovascular growth from the choroid. Peak CNV formation at approximately 14 days post-laser in rodents. First developed in NHP and subsequently adapted to mouse and rat. The standard preclinical efficacy model for anti-VEGF and antiangiogenic therapies targeting wet age-related macular degeneration (AMD).
Advantages
- Standard wet AMD efficacy model — all approved anti-VEGF therapies (ranibizumab, aflibercept, faricimab) validated in laser CNV
- Reproducible CNV lesion formation with quantitative endpoints (fluorescein angiography, OCT, flat-mount area)
- Mouse model enables use of transgenic and knockout strains for mechanistic studies
- NHP laser CNV provides the most translationally relevant model with human-like macular anatomy
- Supports evaluation of intravitreal, subretinal, and suprachoroidal drug delivery routes
Limitations
- Laser-induced injury — does not model the chronic degenerative pathology underlying human wet AMD
- Rodent eyes lack a true macula — limits translational relevance for macular-specific therapeutics
- CNV lesions are self-limiting in rodents (peak at 14 days, regression by 28 days)
- NHP laser CNV studies are extremely expensive ($200K-500K+) with limited animal availability
- Inter-animal variability in lesion size and leakage requires adequate sample sizes (n=8-10 eyes per group)
Regulatory Notes
Laser-induced CNV is the standard preclinical wet AMD efficacy model accepted by FDA and EMA. FDA expects CNV efficacy data with quantitative endpoints (CNV area, fluorescein leakage grade, OCT) in IND pharmacology sections for anti-VEGF and antiangiogenic programs. NHP data is particularly valued for gene therapy and sustained-release intravitreal delivery programs targeting wet AMD.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Experimentica · Charles River Laboratories · Labcorp Drug Development
mdx Mouse Model (Duchenne Muscular Dystrophy)
Preclinical efficacy testing of dystrophin restoration therapies including AAV micro-dystrophin gene therapy, exon skipping ASOs, gene editing (CRISPR), and other DMD therapeutic approaches.
Description
The mdx mouse carries a spontaneous nonsense mutation (premature stop codon) in exon 23 of the Dmd gene, resulting in absence of full-length dystrophin protein. Develops muscle necrosis, regeneration cycles, elevated serum creatine kinase, and progressive diaphragm fibrosis, although limb muscle pathology is milder than human DMD due to compensatory utrophin upregulation. The mdx/mTR double mutant (lacking telomerase) shows more severe progressive disease. The standard preclinical model for DMD gene therapy, exon skipping, and gene editing programs.
Advantages
- Standard DMD model — eteplirsen, casimersen, and golodirsen exon skipping ASOs validated in mdx
- Dystrophin-null phenotype enables clear demonstration of protein restoration efficacy (Western blot, IHC)
- Well-characterized natural history with extensive published functional and histopathological endpoints
- mdx/mTR double mutant provides more severe progressive phenotype for enhanced disease modeling
- Supports biodistribution studies for AAV gene therapy vectors targeting skeletal and cardiac muscle
Limitations
- Milder phenotype than human DMD — compensatory utrophin expression and efficient regeneration in limb muscles
- Diaphragm is the most clinically relevant muscle in mdx — requires specialized functional assessment
- Exon 23 mutation in mouse does not directly model the diverse human DMD mutation spectrum
- Functional endpoints (grip strength, treadmill, rotarod) have high variability requiring large group sizes
- Immune responses to micro-dystrophin or restored dystrophin can confound efficacy interpretation
Regulatory Notes
The mdx mouse is the FDA-expected preclinical efficacy model for DMD programs. FDA has reviewed and accepted mdx efficacy data in multiple DMD gene therapy and exon skipping IND submissions (eteplirsen, SRP-9001/delandistrogene moxeparvovec). FDA expects dystrophin expression quantification (Western blot or mass spectrometry), functional endpoints, and histopathological assessment in the IND pharmacology package.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
The Jackson Laboratory · Charles River Laboratories · Taconic Biosciences
Minipig (Gottingen, Yucatan)
Dermal pharmacology and toxicology, cardiovascular safety, metabolic disease models (diabetes, obesity), wound healing studies, and as an alternative non-rodent to dog.
Description
Purpose-bred miniature pigs (Gottingen or Yucatan strains) increasingly used as a non-rodent alternative to dog for dermal, cardiovascular, and metabolic studies. Skin physiology, wound healing, and metabolic pathways closely resemble human.
Advantages
- Skin most similar to human among laboratory species — gold standard for dermal studies
- Cardiovascular physiology (coronary anatomy, heart rate, ECG parameters) close to human
- Metabolic profile (CYP450 enzymes, insulin sensitivity) closer to human than dog
- Accepted by FDA as alternative non-rodent to dog — growing regulatory acceptance
- Available in defined health status from purpose-bred colonies (Ellegaard Gottingen)
Limitations
- Smaller historical control database compared to Beagle dog — may require concurrent controls
- Larger body size requires more test article than rodents (but less than standard pigs)
- Fewer contract research organizations offer minipig services than dog
- Some biologics may not cross-react with porcine targets
- Growth rate in Yucatan minipigs can complicate chronic studies if not managed
Regulatory Notes
FDA and EMA accept Gottingen minipig as a non-rodent species for toxicology per ICH M3(R2) and S4, especially for dermal products. The 2010 RETHINK project (EU) validated the minipig as a scientifically sound alternative to dog. FDA has accepted minipig as the sole non-rodent in multiple IND submissions, particularly for dermal and cardiovascular programs. Scientific justification for species selection is required.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Ellegaard Gottingen Minipigs · Sinclair Bio Resources · Charles River Laboratories
MPTP-Induced Parkinson's Disease Model
Preclinical efficacy testing of neuroprotective, dopamine-replacement, and neuroregenerative therapies for Parkinson's disease, including gene therapies and cell-based therapies targeting the nigrostriatal pathway.
Description
Neurotoxin-induced Parkinson's disease model using MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), which is converted to MPP+ by monoamine oxidase B (MAO-B) in glia and selectively destroys dopaminergic neurons in the substantia nigra pars compacta via mitochondrial complex I inhibition. C57BL/6 mice are the most susceptible strain. NHP MPTP models produce bilateral parkinsonism with tremor, rigidity, and bradykinesia closely resembling human PD.
Advantages
- Gold standard toxin-induced PD model — MPTP selectively destroys nigrostriatal dopaminergic neurons
- C57BL/6 mouse model is highly reproducible with well-characterized dopamine depletion (>70% in striatum)
- NHP MPTP model produces motor symptoms (tremor, rigidity, bradykinesia) closely resembling human PD
- Multiple MPTP regimens (acute, subacute, chronic) model different aspects of dopaminergic neurodegeneration
- Supports diverse endpoints: behavioral scoring, striatal dopamine HPLC, TH immunohistochemistry, PET imaging
Limitations
- MPTP causes acute dopaminergic cell death — does not model the progressive alpha-synuclein pathology of human PD
- C57BL/6 mice do not develop Lewy body-like inclusions or progressive neurodegeneration after MPTP
- NHP MPTP studies are extremely expensive ($200K-500K+) with significant ethical considerations
- Non-dopaminergic features of PD (cognitive decline, autonomic dysfunction, sleep disturbance) are poorly modeled
- MPTP is highly toxic to humans — requires specialized safety infrastructure and handling protocols
Regulatory Notes
MPTP-induced PD models (mouse and NHP) are accepted by FDA and EMA for preclinical efficacy testing of dopaminergic and neuroprotective therapeutics. For gene therapy programs targeting the CNS, FDA expects efficacy data in a disease-relevant model per the 2020 Gene Therapy Guidance. NHP MPTP data is particularly valued for gene therapy biodistribution and efficacy in a PD-relevant large animal model.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Psychogenics · SNBL (Shin Nippon Biomedical Laboratories)
NASH/MASH Mouse Models (Diet-Induced & Genetic)
Efficacy and pharmacodynamic studies for NASH/MASH therapeutic candidates, including assessment of steatosis, inflammation, ballooning, and fibrosis endpoints.
Description
Diet-induced and genetic mouse models of nonalcoholic steatohepatitis (NASH/MASH) including STAM, MCD diet, Western diet, AMLN diet, and DIAMOND mice. Used for efficacy testing of anti-fibrotic, anti-inflammatory, and metabolic liver disease therapeutics.
Advantages
- Multiple validated models with distinct pathological features
- STAM model develops HCC enabling full disease spectrum assessment
- Western diet models recapitulate human metabolic syndrome context
- Well-characterized histological scoring (NAS score, fibrosis staging)
- Accepted by FDA for efficacy assessment in NASH IND packages
Limitations
- No single model recapitulates all features of human NASH
- MCD diet model lacks metabolic syndrome context (animals lose weight)
- Long induction periods for diet-induced models (12-30+ weeks)
- Spontaneous resolution possible when diet is removed
- Fibrosis development varies significantly between models
Regulatory Notes
FDA accepts NASH/MASH mouse model efficacy data for IND filings. The specific model should be justified based on the drug's mechanism of action. FDA expects histological endpoints assessed by a trained pathologist using the NAFLD Activity Score (NAS) and fibrosis staging. No single model is preferred; scientific justification for model selection is key.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Crown Bioscience · Gubra · Charles River Laboratories
Non-Human Primate (Cynomolgus Macaque)
GLP toxicology for biologics requiring a pharmacologically relevant species, gene therapy biodistribution and toxicology, immunogenicity evaluation, and PK/PD for human-specific biologics.
Description
Cynomolgus macaques are the primary non-human primate species for nonclinical development of biologics, gene therapies, and cell therapies. Highest genetic, immunological, and physiological similarity to humans among standard laboratory species.
Advantages
- Highest target homology and cross-reactivity with human biologics among laboratory species
- Most physiologically relevant species for immune response, PK, and safety assessment
- Required by FDA for most biologics where the drug is pharmacologically active only in primates
- Supports intrathecal, intravitreal, and other clinical routes of administration
- Well-established cardiovascular telemetry and CNS safety pharmacology endpoints
Limitations
- Extremely expensive ($500K-2M+ per GLP study) with long lead times for animal procurement
- Significant ethical and public scrutiny — must demonstrate no alternative species is feasible
- Limited supply and long quarantine periods (6-12 weeks) can delay study start
- Small group sizes (typically 3/sex/group, occasionally 4 with recovery groups) limit statistical power
- Pre-existing AAV and viral seroprevalence can confound gene therapy and vaccine studies
- Global NHP supply constraints (post-2020) have increased pricing and extended procurement timelines
Regulatory Notes
FDA and EMA require NHP toxicology when cynomolgus is the only pharmacologically relevant species per ICH S6(R1). The scientific justification for species selection must include tissue cross-reactivity data. FDA expects a clear explanation of why a lower species is not feasible. For AAV gene therapies, FDA guidance (2020) expects biodistribution and toxicology in NHP when clinically relevant. Group sizes of 3/sex/group are generally accepted for NHP per FDA and EMA.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Labcorp Drug Development · SNBL (Shin Nippon Biomedical Laboratories)
Patient-Derived Xenograft Mouse (PDX)
Translational efficacy studies with high clinical predictive value, biomarker-driven patient selection strategy validation, and resistance mechanism studies.
Description
Immunodeficient mice bearing tumors derived directly from patient surgical specimens, preserving original tumor heterogeneity, architecture, and genomic landscape. The gold standard for translational oncology efficacy.
Advantages
- Preserves patient tumor heterogeneity, architecture, and genomic profile through early passages
- Higher clinical predictive value than CDX — response rates correlate better with clinical outcomes
- Large commercially available PDX banks with full genomic/transcriptomic annotation
- Enables precision medicine approaches — test across multiple PDX models to identify responder populations
- Supports co-clinical trial design (parallel PDX studies during Phase I/II)
Limitations
- Immunodeficient host eliminates immune component of tumor biology
- Tumor engraftment rates vary by indication (50-80% for CRC, <20% for some rare tumors)
- Slow growth (4-12 weeks to establish) limits throughput
- Expensive — $500-2,000+ per mouse with annotated models
- Mouse stroma replaces human stroma over passages, reducing translational relevance
Regulatory Notes
FDA views PDX data favorably for oncology proof-of-concept efficacy (ICH S9). PDX panels demonstrating biomarker-driven responses strengthen IND pharmacology sections. FDA Oncology Division increasingly expects PDX or GEMM data for pivotal nonclinical efficacy, especially for novel targets.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Champions Oncology · Crown Bioscience · The Jackson Laboratory (PDX Resource)
Pig Cardiovascular Model (Yorkshire/Landrace)
Translational cardiovascular efficacy and safety studies including myocardial infarction therapeutics, coronary stent testing, cardiac gene therapy vector delivery, cardiac device evaluation, and cardiovascular safety pharmacology in a large animal model.
Description
The domestic pig is the most translationally relevant large animal model for cardiovascular research due to cardiac anatomy, coronary vasculature, heart-to-body weight ratio (5 g/kg, similar to human), hemodynamics, and electrophysiology closely resembling humans. Supports catheter-based coronary occlusion for myocardial infarction, stent implantation, cardiac device testing, and gene therapy delivery. Right coronary dominance pattern and limited collateral circulation mirror human coronary anatomy.
Advantages
- Cardiac anatomy, coronary vasculature, and heart-to-body weight ratio most similar to human among lab animals
- Catheter-based coronary occlusion closely mimics clinical AMI pattern, tissue injury, and hemodynamic response
- Supports clinically relevant interventions: percutaneous coronary intervention, stent deployment, device implantation
- Well-suited for cardiac gene therapy vector delivery via intracoronary, direct intramyocardial, or retrograde coronary sinus routes
- Electrophysiology (ECG parameters, action potential duration) close to human — accepted for cardiac safety studies
Limitations
- Very high per-study cost ($100K-400K+) including animal procurement, surgical facilities, and specialized imaging
- Rapid growth in standard farm breeds — juvenile pigs can double in weight during a long study, complicating chronic protocols
- Requires dedicated large animal surgical suite with catheterization lab capabilities
- Limited genetic tools compared to mouse — no standard transgenic or knockout pig lines for most targets
- Fewer CROs offer porcine cardiovascular services compared to dog or NHP
Regulatory Notes
Pig cardiovascular models are accepted by FDA and EMA for cardiovascular efficacy and safety studies, cardiac device testing (ISO 5840, FDA cardiovascular device guidance), and coronary stent evaluation. FDA expects porcine data for coronary stent biocompatibility and restenosis assessment. For cardiac gene therapy, FDA accepts pig biodistribution and efficacy data when the pig is the pharmacologically relevant species per the 2020 Gene Therapy Guidance.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Sinclair Bio Resources · Charles River Laboratories · NAMSA
Rabbit (New Zealand White)
Embryo-fetal development toxicity (ICH S5(R3)), ocular safety and pharmacology, dermal safety studies, and pyrogenicity testing.
Description
New Zealand White rabbit used for developmental and reproductive toxicology (DART), immunogenicity studies, ocular pharmacology/toxicology, and dermal irritation/sensitization testing. The standard non-rodent species for embryo-fetal development studies.
Advantages
- Standard species for embryo-fetal development studies — extensive historical control data
- Eye anatomy closer to human than rodent — standard for ocular pharmacology and toxicology
- Well-suited for dermal studies due to skin sensitivity and large surface area
- Better predictor of human immunogenicity than rodents for some biologics
- Relatively lower cost than dog or NHP for non-rodent toxicology applications
Limitations
- Not a standard non-rodent species for general repeat-dose toxicology (dog or NHP preferred)
- Limited genetic tools and disease models compared to mouse or rat
- Sensitive GI tract limits oral dosing utility for some compounds
- Coprophagy can complicate PK interpretation for oral compounds
- Housing and handling requirements are more complex than rodents
Regulatory Notes
Standard species for embryo-fetal development studies per ICH S5(R3). FDA and EMA accept rabbit data for DART, ocular pharmacology/toxicology, and dermal safety. Not typically accepted as the sole non-rodent species for general repeat-dose toxicology unless scientifically justified.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Envigo (Inotiv) · Labcorp Drug Development
Rat (Sprague Dawley, Wistar)
GLP repeat-dose toxicology (rodent species), safety pharmacology core battery, definitive PK/ADME studies, and dose range finding for IND-enabling packages.
Description
Standard outbred rat strains used extensively for regulatory toxicology, safety pharmacology, PK, and ADME studies. Sprague Dawley is the most common toxicology strain; Wistar is widely used in Europe. Larger blood volume and organ size than mouse enables serial sampling.
Advantages
- Gold standard rodent species for GLP toxicology — largest historical control database
- Sufficient blood volume for serial PK sampling without satellite groups
- Well-characterized safety pharmacology endpoints (Irwin, FOB, respiratory, cardiovascular)
- Extensive metabolic enzyme characterization enables human PK prediction
- Larger organ size facilitates surgical procedures and intrathecal dosing
Limitations
- Higher per-animal and housing costs compared to mouse
- Many human-specific biologics do not cross-react with rat targets
- Spontaneous background pathology (e.g., mammary tumors in SD rats) can confound chronic studies
- Metabolic differences from humans (CYP450 isoforms) can limit PK predictivity
- Not suitable for many disease models where genetically modified mice are preferred
Regulatory Notes
Preferred rodent species for GLP toxicology by FDA, EMA, and PMDA per ICH M3(R2) and S6(R1) for biologics. Sprague Dawley is the default toxicology strain in most IND-enabling packages. FDA expects a two-species toxicology package (rat + non-rodent) for most modalities; rat-only may suffice under ICH S9 for oncology.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Envigo (Inotiv) · Taconic Biosciences
Spontaneously Hypertensive Rat (SHR)
Preclinical efficacy testing of antihypertensive agents (ACE inhibitors, ARBs, calcium channel blockers, diuretics, novel targets), cardiovascular safety pharmacology, and long-term end-organ damage studies.
Description
Genetically hypertensive rat model developed from an outbred Wistar colony at Kyoto University (Okamoto and Aoki, 1963). SHR rats develop spontaneous, progressive hypertension beginning at 5-6 weeks of age, reaching systolic blood pressure of 180-200 mmHg by 12-14 weeks, with subsequent cardiac hypertrophy and vascular remodeling. The gold standard genetic hypertension model with Wistar-Kyoto (WKY) rats as normotensive controls.
Advantages
- Gold standard genetic hypertension model — all major antihypertensive drug classes validated in SHR
- Progressive, spontaneous hypertension development without surgical or pharmacological intervention
- Well-matched normotensive control strain (WKY) enables rigorous baseline comparisons
- Develops clinically relevant end-organ damage: cardiac hypertrophy, vascular remodeling, renal changes
- Extensive historical database spanning 60+ years of cardiovascular research
Limitations
- Polygenic model (3+ contributing genes) — does not fully capture the multifactorial complexity of human essential hypertension
- SHR substrain variability across vendors can affect baseline blood pressure and response to treatment
- WKY control strain also has genetic variability between sources — matched sourcing is critical
- Does not model salt-sensitive hypertension, renovascular hypertension, or secondary hypertension subtypes
- Telemetry implantation required for accurate blood pressure assessment adds cost and surgical complexity
Regulatory Notes
SHR is the most widely accepted preclinical hypertension efficacy model by FDA and EMA. Blood pressure data from SHR studies is routinely included in IND pharmacology sections for antihypertensive agents. FDA expects dose-response blood pressure data collected via telemetry or validated non-invasive methods with appropriate WKY normotensive controls.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Envigo (Inotiv) · Taconic Biosciences
Streptozotocin (STZ)-Induced Diabetic Model
Preclinical efficacy testing of insulin secretagogues, GLP-1 receptor agonists, beta cell regeneration therapies, and glucose-lowering agents, as well as diabetic complication studies (nephropathy, neuropathy, retinopathy).
Description
Chemically-induced diabetes model using streptozotocin (STZ), an alkylating agent that selectively destroys pancreatic beta cells via GLUT2-mediated uptake. Single high-dose STZ (150-200 mg/kg mouse, 50-65 mg/kg rat) produces acute Type 1 diabetes; multiple low-dose STZ (40-50 mg/kg x 5 days, mouse) produces autoimmune-mediated beta cell destruction. C57BL/6 mice and Sprague Dawley rats are the most commonly used strains.
Advantages
- Most widely used chemically-induced diabetes model with decades of validation data
- Rapid onset of hyperglycemia (>250 mg/dL within 1 week) enables efficient study timelines
- High-dose and low-dose protocols model Type 1 and autoimmune diabetes, respectively
- Well-established diabetic complication models (nephropathy, neuropathy, retinopathy) for long-term studies
- Low cost and available in multiple species and strains for flexibility in study design
Limitations
- STZ cytotoxicity is not beta-cell-exclusive — can cause hepatic and renal toxicity at high doses
- Single high-dose protocol destroys beta cells completely — cannot model partial insulin deficiency
- Does not capture the insulin resistance and metabolic syndrome features of Type 2 diabetes
- Multiple low-dose protocol variability requires careful dose optimization for each mouse strain and vendor
- STZ-induced diabetes is chemically driven — does not recapitulate the autoimmune etiology of human T1D
Regulatory Notes
STZ-induced diabetes is universally accepted by FDA and EMA for preclinical efficacy testing of antidiabetic therapeutics. FDA expects dose-response data with glycemic endpoints (fasting blood glucose, HbA1c, OGTT) in IND pharmacology sections. For diabetic complication studies, FDA expects histopathological confirmation of end-organ damage (kidney, nerve, retina).
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Crown Bioscience · Gubra
Syngeneic Mouse (Immune-Competent Tumor)
Immuno-oncology efficacy testing (checkpoint inhibitors, oncolytic viruses, cancer vaccines), combination therapy optimization, and tumor immune microenvironment characterization.
Description
Immune-competent mice bearing transplantable murine tumors (e.g., CT26, MC38, B16, 4T1, EMT6). Enables evaluation of immune-mediated anti-tumor activity in the context of an intact immune system.
Advantages
- Intact immune system enables evaluation of immune checkpoint inhibitors and combination IO
- Fast tumor growth (7-14 days) and reproducible kinetics for efficient study design
- Well-characterized immune infiltrate profiles across commonly used models (CT26, MC38, B16)
- Lower cost than humanized immune models while still assessing immune-mediated mechanisms
- Strong historical dataset for benchmarking against anti-PD-1/anti-CTLA-4
Limitations
- Murine tumors — not human biology; limited to surrogate antibodies or cross-reactive agents
- Tumor models are immunogenically 'hot' — may overestimate clinical response rates
- Narrow panel of available tumor types (primarily colon, melanoma, breast, lung)
- Not suitable for testing human-specific biologics without surrogate approach
- Some models have variable response to IO agents depending on passage number
Regulatory Notes
FDA accepts syngeneic models for immuno-oncology proof-of-concept (ICH S9). Particularly valued for demonstrating immune-mediated mechanism of action. FDA expects clear description of the surrogate antibody approach and its relevance to the clinical candidate when using mouse-specific antibodies.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Crown Bioscience · Taconic Biosciences
Transgenic / Knock-In Mouse (Disease-Specific)
Disease-relevant efficacy studies where the therapeutic targets a specific human gene or pathway, especially for rare genetic diseases and neurodegenerative conditions.
Description
Mice engineered to express a human gene, mutant allele, or reporter construct to model specific diseases. Includes overexpression transgenics (e.g., hAPP for Alzheimer's, SOD1-G93A for ALS) and precision knock-in alleles.
Advantages
- Disease-relevant phenotypes enable translational efficacy endpoints
- Human target expression allows testing of species-specific therapeutics
- Well-characterized natural history enables robust study design
- Many models are commercially available or accessible through academic collaborations
- Supports biomarker development that can translate to clinical endpoints
Limitations
- Overexpression transgenics may not fully recapitulate human disease biology
- Genetic background effects can confound phenotype interpretation
- Breeding and colony management can delay study timelines by 8-12 weeks
- Some models have variable penetrance or incomplete phenotypes
- Intellectual property restrictions may limit commercial use of certain models
Regulatory Notes
FDA and EMA accept disease-relevant transgenic and knock-in models for pharmacology and proof-of-concept efficacy (ICH S6(R1) for biologics, ICH S9 for oncology). A scientifically justified rationale for model selection should be included in the IND. For gene therapies, FDA expects efficacy in a disease-relevant model per 2020 Chemistry, Manufacturing, and Control guidance for human gene therapy INDs.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
The Jackson Laboratory · Taconic Biosciences · Charles River Laboratories
Transverse Aortic Constriction (TAC) Heart Failure Mouse Model
Preclinical efficacy testing of cardioprotective agents, antifibrotic therapies, gene therapies targeting cardiac remodeling, and evaluation of novel targets for heart failure with reduced ejection fraction (HFrEF).
Description
Surgically-induced pressure overload model via partial ligation of the transverse aorta between the innominate and left carotid arteries using a 27-gauge needle as a sizing guide. Develops compensated left ventricular hypertrophy within 1-2 weeks, transitioning to decompensated heart failure with reduced ejection fraction (HFrEF) by 4-8 weeks. Cardiac fibrosis, chamber dilation, and impaired systolic function recapitulate key features of human pressure overload-induced heart failure.
Advantages
- Well-characterized transition from compensated hypertrophy to decompensated heart failure
- Extensive molecular characterization of hypertrophy, fibrosis, and heart failure gene programs in C57BL/6
- Compatible with echocardiography, hemodynamic catheterization, and cardiac MRI for functional endpoints
- Supports gene therapy and antisense approaches — large genetic toolkit in C57BL/6 background
- Adjustable severity by needle gauge (25G mild to 27G severe) enables dose-response study design
Limitations
- Acute surgical pressure overload does not model the gradual onset of human hypertensive heart disease
- Significant substrain variability — C57BL/6N develops more consistent HF than C57BL/6J
- Surgical technique variability introduces inter-operator differences in constriction severity
- Post-surgical mortality (10-20%) reduces effective group sizes and may introduce survivor bias
- Does not model ischemic heart failure, HFpEF, or volume overload cardiomyopathy
Regulatory Notes
TAC-induced heart failure is accepted by FDA and EMA for preclinical efficacy testing of cardioprotective and anti-remodeling therapeutics. FDA expects echocardiographic functional endpoints (ejection fraction, fractional shortening), histopathological assessment (fibrosis, hypertrophy), and hemodynamic parameters in IND pharmacology sections for heart failure programs.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Labcorp Drug Development · Taconic Biosciences
Wild-Type Mouse (CD-1, C57BL/6, BALB/c)
Early PK/PD, tolerability screening, dose range finding, and baseline pharmacology for small molecules, peptides, and nucleic acid therapeutics.
Description
Standard inbred or outbred mouse strains used as the workhorse for pharmacology, PK, tolerability, and toxicology studies. CD-1 (outbred) for toxicology, C57BL/6 and BALB/c (inbred) for pharmacology and immunology.
Advantages
- Lowest cost and fastest turnaround of any in vivo model
- Extensive historical control databases for toxicology endpoints
- Well-characterized genetics, physiology, and pharmacology
- Wide availability across multiple vendors with consistent quality
- Extensive reagent and assay ecosystem for biomarker readouts
Limitations
- Limited predictive value for human immune responses and immunogenicity
- Many human targets not cross-reactive in mouse (especially mAbs and bispecifics)
- Short lifespan limits chronic disease modeling
- Small blood volume constrains serial PK sampling (satellite groups often required)
- Metabolic differences can lead to misleading PK predictions for some compound classes
Regulatory Notes
Universally accepted by FDA, EMA, and PMDA as a rodent species for nonclinical pharmacology and toxicology per ICH M3(R2) for small molecules, ICH S6(R1) for biologics, and ICH S9 for oncology therapeutics. CD-1 (outbred) preferred for general mouse toxicology; C57BL/6 widely used for efficacy and pharmacology. Mouse is often the first species in a two-species toxicology package.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
The Jackson Laboratory · Charles River Laboratories · Taconic Biosciences
Woodchuck Hepatitis B Model
Preclinical efficacy testing of HBV antivirals (nucleos(t)ide analogues, capsid assembly modulators), siRNA/ASO targeting HBV, immunomodulatory approaches, and therapeutic vaccines for chronic hepatitis B functional cure.
Description
The eastern woodchuck naturally infected with woodchuck hepatitis virus (WHV), a hepadnavirus closely related to human HBV in morphology, gene structure, replication, and disease progression. Neonatal WHV infection produces chronic carrier state (cccDNA persistence, chronic viremia, immune tolerance) progressing to hepatocellular carcinoma (HCC) at 17-36 months, mirroring human chronic HBV. The gold standard animal model for HBV drug development for over 40 years.
Advantages
- WHV infection is the closest surrogate for human chronic HBV — cccDNA, viremia, immune tolerance, and HCC development
- Drug efficacy and toxicity results in chronic carrier woodchucks are predictive of human clinical responses
- Supports assessment of functional cure endpoints: surface antigen loss, seroconversion, and cccDNA reduction
- Models maternal-to-neonatal transmission and immune tolerance relevant to perinatal HBV infection
- Over 40 years of published validation data supporting regulatory acceptance for HBV drug development
Limitations
- Very limited availability — specialized colonies maintained by few facilities worldwide
- High per-study cost ($100K-300K+) due to animal procurement, housing, and long study durations
- Large body size (3-5 kg) requires substantial test article quantities
- Limited reagent and antibody toolbox compared to standard laboratory species
- WHV genome differs from HBV at the sequence level — some HBV-specific targets may not be conservable
Regulatory Notes
The woodchuck WHV model is the standard preclinical HBV efficacy model accepted by FDA and EMA. Chronic carrier woodchuck data has been included in IND submissions for multiple approved HBV antivirals. FDA expects virologic endpoints (WHV DNA, WHsAg, anti-WHs) and liver histopathology in the IND pharmacology package for HBV programs. The model is particularly valued for combination therapy and functional cure strategies.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Northeastern Wildlife (Harrison, ID) · Georgetown University (Woodchuck HBV Program)
Xenograft Mouse — Cell Line-Derived (CDX)
First-pass in vivo efficacy screening for oncology therapeutics, dose-response characterization, and PK/PD correlation in tumor-bearing hosts.
Description
Immunodeficient mice bearing subcutaneous or orthotopic tumors derived from established human cancer cell lines. The most widely used in vivo oncology model for initial efficacy screening and dose-response.
Advantages
- Fast tumor establishment (7-14 days for most models) with highly reproducible growth kinetics
- Hundreds of well-characterized cell lines available with known genomic/transcriptomic profiles
- Relatively low cost per animal and scalable for dose-response studies
- Orthotopic implantation (e.g., intracranial, orthotopic pancreatic) available for metastasis studies
- Compatible with imaging modalities (luciferase, GFP) for longitudinal monitoring
Limitations
- Lacks tumor microenvironment heterogeneity — clonal, not representative of patient tumors
- Immunodeficient host prevents evaluation of immune-mediated mechanisms
- Subcutaneous implant site is non-physiological for most tumor types
- Many cell lines have drifted from original tumor genetics after extensive passaging
- Poor predictor of clinical response rates — historically low clinical translation rates for oncology drugs tested only in CDX models
Regulatory Notes
Accepted by FDA and EMA for preliminary pharmacology (ICH S9). CDX data alone is generally insufficient for oncology INDs — FDA expects more translationally relevant models (PDX, syngeneic, or GEMM) for pivotal efficacy claims. CDX is appropriate for dose selection and early screening.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Crown Bioscience · Champions Oncology
Zebrafish (Danio rerio)
High-throughput compound screening and toxicity triage, developmental toxicity assessment, cardiovascular safety (heart rate, rhythm, morphology), and early-stage lead prioritization.
Description
Larval and adult zebrafish used for high-throughput toxicity screening, developmental toxicity, and cardiovascular safety assessment. Optical transparency of larvae enables real-time in vivo imaging. Increasingly recognized as a NAM for reducing mammalian testing.
Advantages
- Very high throughput — hundreds of embryos per experiment at minimal cost
- Transparent embryos enable real-time in vivo imaging of organ development and drug effects
- 70% genetic homology to human; well-conserved drug targets for many pathways
- Rapid development (most organs functional by 5 days post-fertilization)
- FDA Modernization Act 2.0 recognizes zebrafish as a valid alternative to mammalian models
Limitations
- Aquatic organism — drug exposure via immersion limits control of PK parameters
- Significant physiological differences from mammals (gills, poikilotherm, regeneration)
- Not accepted as a definitive species for GLP toxicology
- ADME/PK translation to human is limited — metabolism differs substantially
- Some drug targets not conserved or expressed differently in zebrafish
Regulatory Notes
FDA Modernization Act 2.0 (signed December 2022, effective 2023) explicitly recognizes alternatives to mammalian testing, including zebrafish. The April 2025 FDA NAMs Roadmap includes zebrafish as a recognized alternative method for early safety screening. However, zebrafish data does not replace required GLP mammalian studies for IND; it is used to supplement the safety database and prioritize lead compounds. EMA position is similar — supportive but supplementary.
IND Sections Supported
New Approach Methodology (NAM) Context
Can supplement some early mammalian toxicity screens (developmental toxicity, cardiotoxicity) under FDA Modernization Act 2.0. Particularly useful for reducing the number of compounds entering mammalian testing. Not a replacement for GLP studies and FDA has not accepted zebrafish as a mammalian replacement species.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Biobide · InVivo Biosystems · ZeClinics · Charles River Laboratories
Zucker Diabetic Fatty (ZDF) Rat
Preclinical efficacy testing of insulin sensitizers, GLP-1 agonists, SGLT2 inhibitors, and other antidiabetic therapeutics targeting Type 2 diabetes with obesity and insulin resistance.
Description
Genetic Type 2 diabetes model carrying a homozygous leptin receptor mutation (fa/fa) on a Zucker background. Male ZDF rats develop progressive obesity, insulin resistance, hyperinsulinemia, hyperglycemia (400-500 mg/dL by 10-12 weeks), and hyperlipidemia with eventual beta cell failure. The most widely used genetic rat model for T2D drug development, closely recapitulating the metabolic syndrome phenotype of human T2D.
Advantages
- Spontaneous T2D with full metabolic syndrome: obesity, hyperglycemia, hyperinsulinemia, hyperlipidemia
- Progressive disease course mirrors human T2D — insulin resistance followed by beta cell failure
- Well-characterized disease timeline enables intervention at specific disease stages
- Develops diabetic complications (nephropathy, neuropathy) relevant to long-term T2D outcomes
- Commercially available from Charles River with standardized genetic background and quality control
Limitations
- Leptin receptor mutation-driven obesity does not represent polygenic human T2D etiology
- Male-only diabetes development limits study design flexibility — females require high-fat diet for disease
- High per-animal cost ($200-400+ per rat) due to genetic background and breeding requirements
- Aggressive disease progression may mask moderate therapeutic effects — timing of intervention is critical
- Limited utility for testing leptin pathway-targeting therapeutics due to the underlying mutation
Regulatory Notes
ZDF rats are accepted by FDA and EMA as a standard preclinical T2D efficacy model. FDA expects glycemic endpoints (fasting glucose, HbA1c, OGTT, insulin levels) and metabolic parameters (body weight, lipid panel) in IND pharmacology sections. ZDF data has supported numerous antidiabetic drug approvals and is routinely cited in FDA pharmacology reviews.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Charles River Laboratories · Crown Bioscience · Gubra
3D Spheroid Cultures
Medium-throughput cytotoxicity and efficacy screening with improved physiological relevance over 2D, especially for oncology and liver toxicology.
Description
Self-assembled three-dimensional cell aggregates formed from cell lines or primary cells using ultra-low attachment plates, hanging drop, or scaffold methods. Simpler than organoids but capture key 3D features including hypoxia gradients, nutrient diffusion, and cell-cell contact.
Advantages
- Better physiological relevance than 2D monolayer — captures hypoxia gradients and drug penetration
- Higher throughput and lower cost than organoids or organ-on-chip platforms
- Compatible with high-content imaging and standard plate reader formats (96/384-well)
- No Matrigel/BME dependence — simpler and more reproducible than organoids
- Tumor spheroids recapitulate drug resistance mechanisms related to 3D architecture
Limitations
- Less complex than organoids — does not recapitulate organ architecture or cell-type diversity
- Size variability between spheroids can introduce assay variability
- Core necrosis in large spheroids (>500 microns) limits long-term viability
- Limited regulatory qualification as a standalone alternative method
- Drug penetration differences from in vivo tissue may not be fully representative
Regulatory Notes
3D spheroids are accepted as supplementary data in IND submissions but are not qualified as standalone replacements for required studies. FDA views 3D culture data favorably as supporting evidence for mechanism of action and compound selection. Included within the broader NAMs framework under FDA Modernization Act 2.0.
IND Sections Supported
New Approach Methodology (NAM) Context
Part of the broader NAMs ecosystem but not yet qualified as a replacement for specific animal studies. Valuable for compound prioritization before advancing to in vivo testing.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Corning (ultra-low attachment) · InSphero · Greiner Bio-One
ADCC Reporter Bioassay
Lot-release potency testing, Fc engineering optimization, biosimilar comparability, and characterizing ADCC as a mechanism of action for therapeutic antibodies.
Description
Bioluminescent reporter-based cell assay quantifying antibody-dependent cellular cytotoxicity (ADCC) potency through FcgammaRIIIa (CD16a) activation. Engineered effector cells expressing NFAT-luciferase and human FcgammaRIIIa (V158 or F158 variant) are co-cultured with antibody-opsonized target cells. The required potency assay for antibodies with Fc-mediated effector function.
Advantages
- Required regulatory potency assay for antibodies with Fc effector function per ICH Q6B and S6(R1)
- Thaw-and-use effector cells enable same-day assay completion with high reproducibility
- Quantitative dose-response curves suitable for GMP lot-release and stability programs
- V158 and F158 FcgammaRIIIa variants available to assess impact of receptor polymorphism
- Simple add-mix-read luminescent format with low variability and high accuracy
Limitations
- Reporter activation measures receptor signaling, not actual target cell killing — surrogate readout
- Does not capture NK cell heterogeneity or patient-derived immune cell variability
- Requires appropriate target cell line expressing the relevant surface antigen
- Cannot assess complement-dependent cytotoxicity (CDC) — separate assay required
- Limited to Fc-mediated mechanisms — does not capture Fab-mediated cytotoxicity
Regulatory Notes
ADCC potency assays are required for antibodies with Fc effector function per ICH Q6B (Specifications for Biotechnological/Biological Products) and ICH S6(R1). FDA expects ADCC data in the IND for antibodies where ADCC is a proposed mechanism of action. Biosimilar guidance (FDA 2015, EMA) requires functional ADCC comparability studies. Reporter bioassays are accepted as GMP lot-release potency methods.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Promega (ADCC Reporter Bioassay) · WuXi AppTec · Charles River Laboratories
Air-Liquid Interface (ALI) Airway Model
Preclinical evaluation of inhaled therapeutics, pulmonary drug absorption and formulation testing, respiratory virus infection modeling (RSV, influenza, SARS-CoV-2), and airway inflammation/fibrosis studies.
Description
Primary human bronchial epithelial cells cultured at an air-liquid interface on Transwell inserts, differentiating into a pseudostratified mucociliary epithelium with ciliated cells, goblet cells, and basal cells. Commercially available as MucilAir (Epithelix) and EpiAirway (MatTek/Sartorius). Used for inhaled drug efficacy, pulmonary toxicity, respiratory infection modeling, and mucociliary clearance assessment.
Advantages
- Fully differentiated human airway epithelium with functional cilia, mucus production, and tight junctions
- Air-liquid interface mimics physiological exposure route for inhaled therapeutics
- Commercially available with standardized QC (MucilAir, EpiAirway) — reproducible across batches
- Supports direct aerosol/nebulizer deposition for realistic inhaled drug exposure
- Validated for respiratory virus infection modeling including RSV, influenza, and SARS-CoV-2
Limitations
- Does not include immune cells, vasculature, or smooth muscle — limited to epithelial barrier
- Static culture — lacks mechanical breathing motion and airflow dynamics
- Regional airway differences (nasal, bronchial, alveolar) require separate model configurations
- Donor-to-donor variability in primary cells requires characterization and multi-donor panels
- Cannot assess systemic absorption or pulmonary PK beyond barrier transport
Regulatory Notes
ALI airway models are accepted by FDA and EMA as supporting evidence for inhaled drug development programs. Data on mucociliary clearance, barrier integrity, and epithelial toxicity from ALI models is routinely included in IND submissions for inhaled therapeutics. The models are recognized in the FDA NAMs Roadmap (April 2025) as established tools for pulmonary drug development. Not a replacement for in vivo inhalation toxicology but accepted as complementary translational data.
IND Sections Supported
New Approach Methodology (NAM) Context
ALI airway models provide human-relevant pulmonary data that can supplement animal inhalation studies. Increasingly used to reduce the number of in vivo inhalation studies needed during lead optimization. Does not replace required GLP inhalation toxicology studies but can inform study design and de-risk respiratory safety signals.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Epithelix (MucilAir) · MatTek / Sartorius (EpiAirway) · Lonza
Caco-2 Permeability Assay
Oral drug absorption prediction and BCS classification, P-glycoprotein and BCRP efflux liability assessment, and rank-ordering compounds by intestinal permeability during lead optimization.
Description
Polarized monolayer of Caco-2 human colon adenocarcinoma cells cultured on Transwell inserts to measure bidirectional apparent permeability (Papp). The FDA-recognized in vitro surrogate for human intestinal absorption under the Biopharmaceutics Classification System (BCS). Measures passive transcellular and paracellular permeability, efflux ratios (P-gp, BCRP), and active transport.
Advantages
- FDA-recognized BCS permeability surrogate — Caco-2 Papp data accepted for biowaiver applications per FDA M9 guidance
- Well-established 21-day differentiation protocol with tight junction formation and transporter expression
- High throughput in 96-well Transwell format enables screening of large compound libraries
- Bidirectional transport (A-to-B and B-to-A) quantifies efflux ratios for P-gp and BCRP liability
- Extensive published database of reference compound Papp values for assay benchmarking
Limitations
- Derived from colon carcinoma — does not fully recapitulate small intestinal physiology
- Low CYP3A4 expression limits utility for first-pass metabolism assessment
- Paracellular permeability may be underestimated due to tighter junctions than human jejunum
- Batch-to-batch variability requires rigorous QC with reference compounds at each passage
- Does not capture regional intestinal differences (duodenum, jejunum, ileum, colon) in a single assay
Regulatory Notes
Caco-2 permeability is the FDA-recognized in vitro method for BCS permeability classification per the ICH M9 guideline (Biopharmaceutics Classification System-Based Biowaivers, 2019) and FDA ANDA guidance. Papp values are accepted for BCS Class I/III biowaiver applications. The 2020 FDA Drug Interaction Guidance also references Caco-2 for P-gp and BCRP efflux transporter assessment. EMA and PMDA accept equivalent Caco-2 data.
IND Sections Supported
New Approach Methodology (NAM) Context
Caco-2 permeability is an established regulatory alternative to in vivo absorption studies. Under ICH M9, BCS Class I and III drugs with adequate Caco-2 permeability data can obtain biowaivers, eliminating the need for in vivo bioequivalence studies. One of the most mature and widely accepted in vitro NAMs in drug development.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Absorption Systems (Pharmaron) · Cyprotex (Evotec) · Labcorp Drug Development
Co-Culture Systems (Immune + Tumor, etc.)
Immune-mediated cytotoxicity assays (ADCC, CDC, bispecific T-cell engager activity), tumor-immune interaction modeling, and hepatic fibrosis/NASH models.
Description
Multi-cell-type culture systems combining different cell populations (e.g., tumor cells with immune cells, hepatocytes with stellate cells, neurons with glia) to model tissue-level interactions. Available in 2D transwell, 3D spheroid, and microfluidic formats.
Advantages
- Captures cell-cell interactions critical for immune-mediated mechanisms (ADCC, ADCP, T-cell killing)
- ADCC and bispecific T-cell engager assays are established regulatory requirements for biologics
- Enables testing of tumor-immune interactions in a controlled human system
- Modular — can combine specific cell types to address specific biological questions
- Lower cost and higher throughput than humanized mouse models for immune function assays
Limitations
- Complexity of multi-cell systems increases variability and reduces reproducibility
- Ratio of cell types and culture conditions must be carefully optimized for each application
- Does not capture tissue architecture, vascularization, or systemic immune responses
- Donor variability in immune cell function can be significant (multi-donor panels recommended)
- Limited standardization across the field — protocols vary widely between laboratories
Regulatory Notes
ADCC, CDC, and bispecific T-cell engager potency assays are established regulatory requirements for biologics per ICH S6(R1) and ICH Q6B. These co-culture functional assays are required components of the IND package, not alternative methods. Tumor-immune co-cultures for mechanism of action are accepted as supporting pharmacology data.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Promega (ADCC/ADCP reporter assays) · Crown Bioscience · Champions Oncology
Colony Forming Unit (CFU) Hematotoxicity Assay
Predicting myelosuppressive potential and dose-limiting hematotoxicity for oncology therapeutics (ADCs, cytotoxics, PROTACs), and rank-ordering lead candidates by bone marrow toxicity during lead optimization.
Description
Colony forming unit assay using human bone marrow or cord blood-derived hematopoietic progenitor cells cultured in methylcellulose-based semisolid medium. Quantifies drug effects on CFU-GM (granulocyte-macrophage), BFU-E (erythroid), and CFU-GEMM (multilineage) colony formation. Predicts clinical myelosuppression, neutropenia, and thrombocytopenia risk. Validated prediction model correctly predicts human maximum tolerated dose (MTD) for approximately 87% of myelosuppressive drugs.
Advantages
- Human bone marrow progenitor cells provide direct human relevance for hematotoxicity prediction
- CFU-GM IC50 values correlate with clinical MTD — validated prediction model for myelosuppression
- Can supplement or reduce the scope of animal hematotoxicity studies during lead optimization
- Multiple colony types (GM, BFU-E, GEMM) enable assessment of lineage-specific toxicity
- Relatively low cost and established protocol — commercially available progenitor cells and methylcellulose media
Limitations
- Does not capture the bone marrow microenvironment, stromal support, or cytokine signaling context
- Colony scoring is semi-quantitative and requires trained personnel — inter-observer variability exists
- Limited to direct cytotoxic effects — does not predict immune-mediated cytopenias or off-target hematotoxicity
- Donor variability in progenitor cell quality and colony-forming efficiency requires multi-donor panels
- 14-day colony incubation period limits throughput for large compound panels
Regulatory Notes
CFU hematotoxicity data is accepted as supplementary evidence in IND submissions, particularly for oncology and hematology programs. FDA views CFU-GM data as supportive for dose selection and myelosuppression risk assessment. The ICH S9 guidance for oncology therapeutics recognizes the value of in vitro bone marrow toxicity assessment. ECVAM has validated the CFU-GM assay as a scientifically valid alternative for predicting drug-induced neutropenia.
IND Sections Supported
New Approach Methodology (NAM) Context
CFU hematotoxicity assays can supplement in vivo hematotoxicity assessment by providing human-relevant bone marrow toxicity data. Can reduce the number of compounds advanced to in vivo testing and help interpret clinical relevance of animal hematotoxicity findings. ECVAM-validated as a scientifically valid method for predicting drug-induced neutropenia.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Discovery Life Sciences · ReachBio Research Labs · STEMCELL Technologies
Cytokine Release Assay (CRA)
Predicting CRS risk for bispecific antibodies, T-cell engagers, CAR-T therapies, and other immunomodulatory biologics before FIH dosing.
Description
In vitro cytokine release assay systems using human PBMCs or whole blood to predict cytokine release syndrome (CRS) risk for immunomodulatory biologics, bispecific T-cell engagers, and CAR-T cell therapies. Includes wet-coat, dry-coat, and aqueous incubation methods.
Advantages
- Human-relevant immune response prediction
- Multiple validated assay formats (whole blood, PBMC, solid-phase)
- Can test multiple concentrations and donor variability
- Required by FDA for T-cell engaging biologics
- Results directly inform FIH starting dose selection
Limitations
- High donor-to-donor variability requires multiple donors (minimum 6-10)
- Static systems do not capture in vivo pharmacokinetics
- False negatives possible for slow-onset CRS mechanisms
- No standard regulatory-accepted protocol exists across all agencies
Regulatory Notes
FDA expects cytokine release data for immunomodulatory biologics per ICH S6(R1) and the 2022 FDA guidance on bispecific antibodies. EMA Guideline on Strategies to Identify and Mitigate Risks for FIH and Early Clinical Trials (2017) specifically requires CRA for high-risk biologics. Results inform the minimum anticipated biological effect level (MABEL) for FIH dose selection.
IND Sections Supported
New Approach Methodology (NAM) Context
Cytokine release assays are a required human-cell-based assay, not an animal replacement per se, but they provide critical human-relevant safety data that animal models cannot predict. CRS in NHP does not reliably predict human CRS severity.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Labcorp Drug Development · Charles River Laboratories · SGS
FcRn Binding Assay (Antibody PK Prediction)
Predicting therapeutic antibody serum half-life, optimizing Fc-engineered variants for extended PK, biosimilar FcRn binding comparability, and rank-ordering antibody candidates by expected PK profile.
Description
Surface plasmon resonance (SPR) or biolayer interferometry (BLI) assay measuring antibody binding to the neonatal Fc receptor (FcRn) at pH 6.0 (endosomal) and pH 7.4 (physiological). FcRn-mediated IgG recycling is the primary determinant of antibody serum half-life. pH-dependent binding (strong at pH 6.0, minimal at pH 7.4) predicts favorable in vivo PK. Used for Fc engineering optimization, biosimilar comparability, and PK prediction during lead selection.
Advantages
- pH-dependent FcRn binding affinity strongly correlates with antibody serum half-life in humans
- Rapid and cost-effective screening of Fc-engineered variants for optimal PK properties
- Quantitative KD, kon, and koff values at pH 6.0 and pH 7.4 enable precise structure-PK relationships
- Required for biosimilar comparability studies to demonstrate equivalent FcRn binding
- Supports IgG subclass selection and Fc mutation optimization early in antibody engineering
Limitations
- FcRn binding alone does not fully predict in vivo half-life — target-mediated drug disposition (TMDD) is a major confounder
- SPR assay configuration (ligand vs. analyte orientation) can significantly affect binding kinetics
- Does not capture FcRn recycling efficiency in intact cells — cellular FcRn recycling assays provide complementary data
- Moderate throughput — SPR/BLI typically evaluates 10-50 candidates per day, not suitable for large library screening
- Human FcRn vs. mouse FcRn binding can differ — human FcRn transgenic mice needed for in vivo PK confirmation
Regulatory Notes
FcRn binding characterization is an expected component of the biophysical and functional characterization package for therapeutic antibodies per ICH Q6B and S6(R1). FDA expects FcRn binding data for biosimilar comparability assessments per the 2015 FDA Biosimilar Guidance. FcRn binding affinity at pH 6.0 and pH 7.4 is a standard quality attribute for antibody characterization in Module 3.2.S (Drug Substance) and Module 2.6.4 (PK).
IND Sections Supported
New Approach Methodology (NAM) Context
FcRn binding assays provide human-relevant PK prediction data that can inform and optimize in vivo PK study design, potentially reducing the number of antibody candidates advanced to animal PK studies. A well-characterized FcRn binding profile supports human PK prediction models.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Carterra · Cytiva (Biacore SPR systems) · Sartorius (Octet BLI systems)
Human Liver Microsomes (HLM)
CYP inhibition screening for DDI risk assessment, metabolic stability half-life determination, reaction phenotyping to identify contributing CYP isoforms, and metabolite identification studies.
Description
Subcellular fractions prepared from human liver tissue containing CYP450 enzymes, UGTs, FMOs, and other Phase I/II metabolizing enzymes. Used for metabolic stability, CYP inhibition (IC50/Ki), CYP reaction phenotyping, and metabolite identification. Pooled HLM from 50-200 donors captures population-level metabolic variability.
Advantages
- FDA-required test system for in vitro CYP inhibition and metabolic stability per 2020 Drug Interaction Guidance
- Pooled HLM (50-200 donors) captures population-level metabolic variability in a single preparation
- Well-characterized CYP isoform selectivity with validated probe substrates for all major CYP enzymes
- Cost-effective and high-throughput — enables early-stage metabolic liability screening
- Extensive published reference data enables benchmarking and IVIVE (in vitro-in vivo extrapolation)
Limitations
- Does not contain cytosolic enzymes (aldehyde oxidase, xanthine oxidase) — may underestimate clearance for some compounds
- Lacks intact cellular architecture — cannot assess transporter-mediated uptake or biliary efflux
- CYP induction cannot be assessed in microsomes (requires intact hepatocytes)
- Non-CYP metabolism (AO, UGT, SULTs) may be incompletely represented depending on preparation method
- Protein binding in incubations can affect apparent IC50 values — free fraction correction often needed
Regulatory Notes
HLM-based CYP inhibition studies are required by FDA, EMA, and PMDA per the 2020 FDA In Vitro Drug Interaction Guidance and ICH M12 (Drug Interaction Studies, 2024). The guidance specifies HLM as an acceptable test system for reversible and time-dependent CYP inhibition assessment. Metabolic stability data from HLM is a standard component of the ADME package supporting IND filings (Module 4.2.2).
IND Sections Supported
New Approach Methodology (NAM) Context
HLM-based CYP inhibition and metabolic stability assays are established regulatory requirements that directly inform human DDI risk without animal studies. These in vitro human-tissue-derived assays are foundational components of the IND ADME package, not novel NAMs.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
BioIVT · Xenotech (BioIVT) · Corning Life Sciences
Immortalized Cell Lines
High-throughput screening, potency/EC50 determination, reporter-based mechanism assays, manufacturing cell line development, and permeability assessment (Caco-2).
Description
Established human or animal cell lines maintained indefinitely in culture (e.g., HEK293, HepG2, CHO, Caco-2, HeLa, A549). Used for target engagement, reporter assays, potency testing, and early safety screening.
Advantages
- Unlimited supply, highly reproducible results, and very low cost per assay
- Extensive published characterization and protocol literature
- Easy to genetically modify for reporter assays, knockouts, or overexpression
- Caco-2 permeability is an FDA-recognized surrogate for intestinal absorption
- Standard tool for Ames test (genotoxicity) and hERG channel screening
Limitations
- Genetic and phenotypic drift from passage — may not represent native tissue biology
- Often derived from tumor cells — aberrant signaling and metabolic pathways
- Two-dimensional monolayer does not capture tissue architecture or cell-cell interactions
- Many cell lines are misidentified or cross-contaminated (STR authentication essential)
- Limited metabolic competence (e.g., HepG2 vs. primary hepatocytes for CYP activity)
Regulatory Notes
Cell line-based assays are integral to the IND package: hERG assay (CHO/HEK-hERG) required per ICH S7B, Ames test (bacterial) per ICH S2(R1), Caco-2 permeability accepted per FDA ANDA guidance. Cell-based potency assays are required for biologics per ICH Q6B. These are foundational tools, not alternative methods.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
ATCC · Sigma-Aldrich (Merck) · Thermo Fisher Scientific
iPSC-Derived Cardiomyocytes
Proarrhythmia risk assessment under FDA CiPA paradigm, cardiotoxicity screening for oncology therapeutics (ADCs, kinase inhibitors), and mechanistic cardiac safety studies.
Description
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) for cardiac safety assessment, including electrophysiology (multi-electrode array, patch clamp), contractility, and structural cardiotoxicity. Central to the FDA CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative.
Advantages
- Human cardiac physiology — functional ion channels, contractile machinery, and calcium handling
- Central component of FDA CiPA initiative for mechanistic proarrhythmia risk assessment
- Multi-electrode array format enables medium-throughput cardiac safety screening
- Patient-specific iPSC lines can model genetic cardiomyopathies and pharmacogenomic variation
- Reduces reliance on animal cardiovascular telemetry for early safety triage
Limitations
- Immature phenotype — fetal-like electrophysiology and sarcomere organization
- Batch-to-batch variability between iPSC-CM lots requires standardized QC
- Does not capture whole-heart physiology (conduction system, autonomic regulation)
- CiPA paradigm is complementary to, not a replacement for, in vivo cardiovascular telemetry for IND
- Relatively high cost per assay compared to hERG cell lines
Regulatory Notes
FDA CiPA initiative (2013-present) positions hiPSC-CMs as a key component of next-generation cardiac safety assessment alongside in silico ion channel models and clinical TQT alternatives. The ICH S7B/E14 Q&A (2022) endorses a 'best practices' approach incorporating hiPSC-CM data. FDA has accepted hiPSC-CM data in INDs as supplementary cardiac safety evidence. Not yet a standalone replacement for in vivo cardiovascular telemetry in GLP packages, but increasingly influential in clinical hold decisions.
IND Sections Supported
New Approach Methodology (NAM) Context
Under the FDA CiPA initiative, hiPSC-CM data combined with in silico modeling can supplement the scope of in vivo cardiovascular safety pharmacology. The April 2025 FDA NAMs Roadmap identifies iPSC-derived cells as a priority NAM. Does not currently replace the in vivo cardiovascular telemetry study required for IND, but can reduce the need for follow-up animal studies and support clinical risk assessment.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
FUJIFILM Cellular Dynamics (CDI) · Ncardia · Axion BioSystems
iPSC-Derived Hepatocytes
Hepatotoxicity screening in lead optimization, liver disease modeling (NASH, genetic liver diseases), and long-term repeat-exposure toxicity studies not feasible with primary hepatocytes.
Description
Human iPSC-derived hepatocyte-like cells for drug metabolism, hepatotoxicity screening, and liver disease modeling. Offer unlimited supply and genetic consistency compared to primary hepatocytes, though with an immature metabolic phenotype.
Advantages
- Unlimited supply with genetic consistency (no donor variability between experiments)
- Patient-specific iPSC lines enable modeling of genetic liver diseases
- Suitable for long-term exposure studies (weeks) not possible with primary hepatocytes
- Can generate isogenic disease/control pairs using gene editing
- Scalable production for medium-throughput hepatotoxicity screening
Limitations
- Immature metabolic phenotype — lower CYP450 activity than primary hepatocytes
- Not accepted by FDA as a replacement for primary hepatocytes in regulatory CYP studies
- Incomplete hepatocyte polarization and bile canaliculi formation in most protocols
- Higher cost than primary hepatocytes on a per-experiment basis
- Differentiation protocols require 2-4 weeks and specialized expertise
Regulatory Notes
FDA does not currently accept iPSC-derived hepatocytes as a substitute for primary human hepatocytes in required CYP inhibition/induction studies (per 2020 Drug Interaction Guidance). However, iPSC-hepatocyte data can supplement the safety database for hepatotoxicity risk assessment. The FDA NAMs Roadmap (2025) includes iPSC-hepatocytes as a development priority for future DILI prediction models.
IND Sections Supported
New Approach Methodology (NAM) Context
Cannot currently replace primary human hepatocyte studies required for IND. Potential future NAM for chronic hepatotoxicity assessment and personalized DILI risk prediction as maturation protocols improve.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
FUJIFILM Cellular Dynamics (CDI) · Takara Bio · pixlbio (formerly DefiniGEN)
iPSC-Derived Kidney Organoids / Proximal Tubule Cells
Early nephrotoxicity screening, renal transporter assessment, and kidney disease modeling for genetic and metabolic kidney disorders.
Description
Human iPSC-derived kidney organoids and proximal tubule cells for nephrotoxicity screening and kidney disease modeling. Recapitulate key renal transporter expression and tubular injury responses.
Advantages
- Human-relevant nephrotoxicity without animal studies
- Express key renal transporters (OAT1, OAT3, OCT2)
- Patient-specific disease modeling with iPSC from affected individuals
- Amenable to high-content imaging and biomarker readouts
Limitations
- Immature phenotype compared to adult kidney tissue
- Incomplete nephron segmentation in current protocols
- Limited validation for regulatory submissions
- Variable differentiation efficiency across protocols
- Cannot model systemic hemodynamic effects on kidney function
Regulatory Notes
Not yet accepted as a standalone nephrotoxicity assessment for IND. FDA Modernization Act 2.0 enables inclusion as supportive data. The April 2025 FDA NAMs Roadmap identifies kidney models as a priority area for qualification.
IND Sections Supported
New Approach Methodology (NAM) Context
Can supplement in vivo renal safety assessment by providing mechanistic kidney injury data. Potential to reduce animal use in early nephrotoxicity screening, but does not currently replace required in vivo renal endpoints.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Ncardia · STEMCELL Technologies · Corning Life Sciences
iPSC-Derived Neurons
CNS target validation and engagement, neurotoxicity screening, disease modeling for neurodegeneration, and seizure liability assessment.
Description
Human iPSC-derived neurons (cortical, motor, dopaminergic, sensory) and mixed neuronal cultures for CNS target engagement, neurotoxicity screening, and disease modeling (e.g., ALS, Parkinson's, Alzheimer's). Multi-electrode array platforms enable functional readouts.
Advantages
- Human neurons with disease-relevant mutations for patient-specific disease modeling
- Multi-electrode arrays enable functional seizure liability and neurotoxicity screening
- Motor neurons available for ALS and SMA modeling
- Dopaminergic neurons for Parkinson's disease target validation
- Avoids species differences in CNS pharmacology (receptor subtypes, ion channels)
Limitations
- Immature neuronal phenotype — limited synapse formation and network complexity
- Long maturation time (4-8 weeks) to achieve functional electrophysiology
- Does not capture blood-brain barrier, glial interactions, or circuit-level function
- Significant variability between iPSC lines and differentiation batches
- No established regulatory pathway for using iPSC-neuron data in lieu of in vivo CNS safety
Regulatory Notes
FDA recognizes iPSC-derived neurons as a promising NAM for CNS safety and efficacy evaluation. Data can be included in IND submissions as supporting information in Module 4.2.1 (pharmacology). The April 2025 FDA NAMs Roadmap identifies iPSC-derived neural models as a priority development area. Not yet accepted as a replacement for in vivo CNS safety pharmacology (Irwin test/FOB) required by ICH S7A.
IND Sections Supported
New Approach Methodology (NAM) Context
Potential to supplement in vivo CNS safety assessment (Irwin/FOB) with human-relevant seizure liability data. Recognized in FDA NAMs Roadmap but not yet qualified as a standalone replacement for any required in vivo CNS study.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
FUJIFILM Cellular Dynamics (CDI) · BrainXell · Ncardia
Mixed Lymphocyte Reaction (MLR)
Demonstrating functional immune activation by checkpoint inhibitors, bispecific antibodies, and immunomodulatory therapeutics in an allogeneic T-cell response context.
Description
In vitro functional immune assay co-culturing allogeneic PBMCs (or dendritic cells with T cells) to assess T-cell activation, proliferation, and cytokine release. The standard in vitro efficacy assay for checkpoint inhibitors, bispecific T-cell engagers, and immunomodulatory agents. Two-round MLR protocols improve sensitivity for anti-PD-1/PD-L1 and other IO agents.
Advantages
- Standard IO efficacy assay — demonstrates functional T-cell activation by immune checkpoint inhibitors
- Two-round MLR protocol enhances sensitivity for detecting dose-dependent anti-PD-1/PD-L1 activity
- Human immune cells provide species-relevant data for human-specific biologics
- Multi-readout: T-cell proliferation, IFN-gamma, IL-2, TNF-alpha, and cytotoxicity
- Relatively low cost and fast turnaround compared to in vivo humanized mouse IO models
Limitations
- Allogeneic response may not fully represent tumor antigen-specific T-cell activation
- High donor-to-donor variability requires multi-donor panels (minimum 6-10 donors recommended)
- Does not capture tumor microenvironment, stromal interactions, or immune suppressive mechanisms
- Static culture conditions do not recapitulate in vivo PK exposure profiles
- Single-round MLR may lack sensitivity for some checkpoint inhibitors — two-round protocol preferred
Regulatory Notes
MLR and T-cell activation assays are standard components of the pharmacology package for immuno-oncology biologics per ICH S6(R1). FDA expects in vitro functional immune activation data for checkpoint inhibitors and T-cell engaging biologics to support the mechanism-of-action rationale in Module 2.6.2. MLR data is routinely included in IND submissions for IO programs.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Crown Bioscience · Champions Oncology · Charles River Laboratories
Patient-Derived Organoids
Patient-stratified oncology efficacy screening, precision medicine companion diagnostics development, modeling rare diseases, and drug resistance mechanism studies.
Description
Self-organizing three-dimensional tissue structures derived from patient tumor biopsies, normal tissue stem cells, or iPSCs. Recapitulate organ architecture, cell-type diversity, and disease pathology. Available for tumor (PDO), intestinal, liver, kidney, brain, and lung tissue.
Advantages
- Three-dimensional architecture recapitulates native tissue organization and cell-type heterogeneity
- Patient-derived tumor organoids (PDOs) preserve inter-patient genomic diversity and drug response
- Living biobanks enable screening across many patient genotypes — supports patient stratification
- Enables co-culture with immune cells for immuno-oncology applications
- FDA Modernization Act 2.0 recognizes organoids as a valid alternative testing method
Limitations
- Variable establishment rates — not all patient samples form organoids successfully
- Lacks vascularization, immune component (unless co-cultured), and systemic PK context
- Matrigel/BME dependence introduces batch variability and limits scalability
- Standardization of culture conditions and readouts still evolving across the field
- Longer timeline and higher cost than 2D cell line assays
Regulatory Notes
FDA Modernization Act 2.0 and the April 2025 FDA NAMs Roadmap explicitly recognize organoids as new approach methodologies. FDA has accepted organoid data in INDs as supporting evidence for pharmacology (Module 4.2.1) and mechanism of action. The FDA Oncology Center of Excellence has highlighted PDOs as a tool for precision oncology development. Not yet qualified as a standalone replacement for in vivo efficacy studies, but increasingly valued as complementary translational data.
IND Sections Supported
New Approach Methodology (NAM) Context
Under FDA Modernization Act 2.0, organoid-based efficacy data can supplement certain animal pharmacology studies, particularly in oncology where PDOs can demonstrate patient-relevant efficacy. Only one precedent case of FDA accepting organoid data in lieu of an animal study; general regulatory position still requires in vivo data for most programs. Organoid data is increasingly included in IND pharmacology packages alongside in vivo data.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
HUB Organoids (Hubrecht Institute) · Crown Bioscience · STEMCELL Technologies
Primary Human Cell Cultures
Human-relevant PK/ADME (hepatocyte clearance, CYP inhibition/induction), immune cell functional assays, target engagement, and mechanism-of-action confirmation.
Description
Cells isolated directly from human donor tissue (hepatocytes, PBMCs, endothelial cells, fibroblasts, cardiomyocytes, etc.) for pharmacology, toxicology, and ADME studies. Retain donor phenotype and metabolic function for limited passages.
Advantages
- Directly human-relevant — no species translation issues
- Cryopreserved hepatocytes are the gold standard for CYP inhibition/induction (FDA guidance)
- PBMCs enable human immune functional assays (cytokine release, ADCC, CDC)
- Multi-donor panels capture population variability in drug metabolism
- Regulatory agencies specifically require human hepatocyte data for DDI risk assessment
Limitations
- Limited lifespan (hours to days for hepatocytes) — not suitable for chronic exposure studies
- Donor-to-donor variability requires adequate donor pooling or multi-donor panels
- Loss of phenotype and function with passaging — must use at low passage number
- Supply and quality can be inconsistent for rare tissue types
- Two-dimensional culture may not capture in vivo tissue architecture effects
Regulatory Notes
Human hepatocytes (fresh or cryopreserved) are required by FDA for in vitro CYP inhibition and induction studies per the 2020 FDA Drug Interaction Guidance. Human PBMCs are standard for cytokine release assays and immunogenicity risk assessment. Data from primary human cells directly supports Modules 4.2.2 (ADME) and 2.6.6/4.2.3 (immunogenicity). These are established, required components of the IND package, not optional NAMs.
IND Sections Supported
New Approach Methodology (NAM) Context
Human hepatocyte CYP studies are regulatory requirements that replaced historical animal studies. Cytokine release assays (Stebbings method) are increasingly accepted as alternatives to in vivo immunogenicity assessment. Part of the standard IND package, not a novel NAM.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
BioIVT · Lonza · Thermo Fisher Scientific
Reconstructed Human Skin Models (EpiDerm, Episkin)
Regulatory-accepted skin safety testing without animal use. OECD-validated replacement for Draize rabbit skin test.
Description
Commercially produced, standardized reconstructed human epidermis models for skin irritation, corrosion, and sensitization testing. OECD-validated with full regulatory acceptance.
Advantages
- OECD-validated (TG 431, TG 439, GL 497)
- Full regulatory acceptance as animal replacement
- Standardized and commercially available
- High reproducibility across batches
- No animal use required
Limitations
- Limited to skin endpoint assessment
- Does not model systemic absorption
- No immune cell component in basic models
- Cannot assess chronic dermal toxicity
Regulatory Notes
Fully accepted by FDA, EMA, and OECD as replacement for animal skin irritation (TG 439) and corrosion (TG 431) testing. OECD Guideline 497 Defined Approaches accepted for skin sensitization. One of the most successful NAM categories with complete regulatory acceptance.
IND Sections Supported
New Approach Methodology (NAM) Context
Fully validated replacement for Draize rabbit skin irritation/corrosion test and guinea pig sensitization test. One of the few NAMs with complete regulatory acceptance across all major agencies.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
MatTek (EpiDerm) · Episkin (L'Oreal) · SkinEthic
Tumorigenicity Assay (Soft Agar + In Vivo)
Assessing insertional mutagenesis and oncogenic transformation risk for lentiviral CAR-T, gene-edited cell therapies, and iPSC-derived cell therapies.
Description
Soft agar colony formation assay and in vivo tumorigenicity testing to assess the oncogenic potential of genetically modified cell therapy products. Required for cell therapies using integrating vectors (lentiviral, retroviral) or gene editing.
Advantages
- Required safety assessment for integrating vector cell therapies
- Soft agar assay is well-established and standardized
- In vivo tumorigenicity provides functional assessment
- Addresses a key regulatory concern for cell therapy INDs
Limitations
- Soft agar assay sensitivity varies by cell type
- In vivo tumorigenicity requires immunodeficient mice with long observation periods (4-6 months)
- May not detect slow-onset transformation
- Assay design for gene-edited products is still evolving
Regulatory Notes
Required per FDA guidance on CAR-T products (2024) and CBER guidance on testing integrating vector-modified cell products. The FDA expects tumorigenicity assessment for all cell therapy products using integrating vectors. Soft agar colony formation is the standard in vitro assay; in vivo tumorigenicity in NSG mice may also be required.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
WuXi AppTec · Charles River Laboratories · Labcorp Drug Development
BBB-Chip (Blood-Brain Barrier)
CNS drug penetration prediction, BBB permeability ranking, and brain-targeted delivery vehicle evaluation for therapeutics that must cross or specifically avoid the BBB.
Description
Microfluidic device modeling the human blood-brain barrier with brain microvascular endothelial cells, pericytes, and astrocytes under flow. Recapitulates tight junction formation, efflux transporter activity (P-gp, BCRP), and BBB permeability relevant to CNS drug development.
Advantages
- Human BBB cells with functional tight junctions and efflux transporters (P-gp, BCRP, MRP)
- Enables CNS penetration assessment earlier in development than in vivo CSF sampling
- Can model neuroinflammation-induced BBB disruption (relevant for MS, stroke, glioma)
- Supports evaluation of brain-targeted delivery vehicles (transferrin receptor antibodies, etc.)
- Higher TEER values and more physiological permeability than static transwell models
Limitations
- BBB complexity (neurovascular unit) not fully captured — missing neurons and microglia
- Shear stress and flow conditions require careful calibration to achieve physiological TEER
- Limited validation against clinical CNS penetration data (Kp,brain) for diverse chemical space
- Low throughput — not suitable for large compound library screening
- TEER values still below in vivo levels in most platforms
Regulatory Notes
BBB-Chip is recognized by FDA as a research tool for CNS drug development but does not have formal regulatory qualification. Data can be included in IND submissions as supporting rationale for CNS targeting strategy. FDA has not established specific acceptance criteria for BBB-Chip data. The technology is earlier in the regulatory qualification pathway than Liver-Chip or Kidney-Chip.
IND Sections Supported
New Approach Methodology (NAM) Context
Does not currently replace any required animal studies. Useful as a supplementary tool to support CNS targeting rationale and reduce the number of compounds advanced to in vivo BBB penetration studies.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Emulate · Mimetas (OrganoPlate) · SynVivo
Gut-Chip (Intestine MPS)
Oral drug absorption prediction, intestinal toxicity assessment, first-pass metabolism evaluation, and microbiome-drug interaction studies.
Description
Microfluidic device with human intestinal epithelial cells (Caco-2 or primary) and vascular endothelium under peristalsis-like mechanical motion. Recapitulates villus-like morphology, mucus layer, transporter function, and microbiome interactions.
Advantages
- Villus-like 3D morphology under flow — more physiological than static Caco-2 transwell
- Supports microbiome co-culture to assess drug-microbiome interactions
- Captures mucus layer, transporter function, and first-pass metabolism
- Mechanical motion improves differentiation and tight junction formation
- Demonstrates improved permeability prediction compared to static Caco-2 for certain compound classes
Limitations
- Static Caco-2 transwell remains the regulatory standard for BCS-based permeability classification
- Microbiome co-culture protocols not yet standardized or validated for regulatory use
- Limited throughput compared to standard Caco-2 assays
- Higher cost and complexity without clear regulatory advantage for most applications
- Does not capture regional intestinal differences (duodenum vs. ileum vs. colon) in a single device
Regulatory Notes
FDA recognizes Gut-Chip as a promising NAM but Caco-2 transwell remains the accepted standard for BCS permeability classification per FDA ANDA guidance. Gut-Chip data can be included as supplementary information in INDs. The technology is valued for mechanistic understanding of oral absorption and intestinal toxicity but does not yet have a qualified regulatory application.
IND Sections Supported
New Approach Methodology (NAM) Context
Potential to replace some animal oral absorption studies in the future, but Caco-2 transwell is already an established in vitro alternative for permeability. Gut-Chip adds value for microbiome interactions and complex absorption questions beyond standard Caco-2 capability.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Emulate · Mimetas · CN Bio Innovations
Kidney-Chip (Microphysiological System)
Nephrotoxicity risk prediction, renal transporter-mediated drug interaction assessment, and mechanistic investigation of kidney injury biomarkers (KIM-1, NGAL).
Description
Microfluidic device with human proximal tubule epithelial cells and vascular endothelium under physiological shear stress. Recapitulates renal transporter function, drug-induced nephrotoxicity, and tubular reabsorption/secretion relevant to renal drug clearance.
Advantages
- Functional renal transporters (OAT1, OAT3, OCT2, MATE) under flow conditions
- Predicts clinical nephrotoxicity better than static proximal tubule cell cultures
- Cisplatin nephrotoxicity model validated across multiple platforms
- Translational biomarker readouts (KIM-1, NGAL, clusterin) aligned with clinical markers
- Supports renal drug-drug interaction assessment per FDA Drug Interaction Guidance
Limitations
- Proximal tubule focus — does not capture glomerular filtration or collecting duct function
- Limited throughput compared to plate-based renal cell assays
- Not yet qualified for standalone regulatory decision-making
- Complex setup and specialized expertise required
- Does not capture systemic hemodynamic effects on renal function
Regulatory Notes
FDA has engaged with Kidney-Chip technology through the IQ MPS Affiliate program. The 2025 NAMs Roadmap includes kidney MPS as a priority platform. FDA has accepted Kidney-Chip data in INDs as supplementary nephrotoxicity evidence. A formal qualification effort for nephrotoxicity prediction is ongoing. Not yet accepted as a replacement for in vivo renal safety endpoints in GLP studies.
IND Sections Supported
New Approach Methodology (NAM) Context
Can supplement animal nephrotoxicity data with human-relevant mechanistic evidence under FDA Modernization Act 2.0. Particularly valuable when animal studies show renal signals of uncertain human relevance, or to assess renal transporter-mediated DDI risk. Not yet accepted as a replacement for in vivo renal safety endpoints.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Emulate · Nortis · Mimetas
Liver-Chip (Microphysiological System)
DILI risk prediction and mechanistic hepatotoxicity assessment, especially for compounds with clinical liver signals not detected by standard in vitro or animal models.
Description
Microfluidic device containing primary human hepatocytes and non-parenchymal cells (stellate, Kupffer, endothelial) under physiological flow conditions. Recapitulates liver zonation, bile canaliculi, and metabolic function for drug-induced liver injury (DILI) prediction.
Advantages
- Demonstrated 80% sensitivity and 100% specificity across 27 blinded compounds (87% with protein-binding correction) in Emulate validation studies
- Maintains hepatocyte function and CYP activity for 28+ days under flow
- Multicellular composition captures immune-mediated and idiosyncratic hepatotoxicity mechanisms
- Emulate Liver-Chip accepted into FDA's ISTAND qualification pathway (2024)
- Significantly better DILI prediction than standard 2D hepatocyte cultures or animal models
Limitations
- High per-chip cost ($1,000-3,000 per chip) limits throughput
- Specialized equipment and trained operators required
- Limited commercial availability of validated, standardized protocols
- Does not capture systemic exposure, enterohepatic circulation, or multi-organ interactions
- Throughput remains low compared to plate-based assays (typically 12-48 chips per study)
Regulatory Notes
FDA has engaged extensively with Liver-Chip technology. The FDA IQ MPS Affiliate program completed a Liver-Chip DILI qualification in 2023-2024. The April 2025 FDA NAMs Roadmap identifies Liver-Chip as a lead NAM for DILI prediction. Emulate Liver-Chip was accepted into FDA's ISTAND qualification pathway in 2024. EMA engaging through Innovation Task Force and 3Rs Working Party (established 2023). This is the most advanced organ-on-chip platform for regulatory acceptance.
IND Sections Supported
New Approach Methodology (NAM) Context
Liver-Chip can supplement certain animal hepatotoxicity studies under FDA Modernization Act 2.0. Most commonly used to de-risk DILI signals that appear in animal studies but may not be human-relevant, or to detect human-specific DILI risk not seen in animals. Regulatory acceptance is advancing through the ISTAND pathway but full replacement of required animal studies is not yet established.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Emulate · CN Bio Innovations · Mimetas
Lung-Chip (Microphysiological System)
Inhaled drug safety and efficacy testing, pulmonary drug absorption assessment, respiratory infection modeling, and pulmonary inflammation/fibrosis studies.
Description
Microfluidic device with human alveolar or airway epithelial cells at an air-liquid interface above a vascular endothelial channel with mechanical breathing motions. Recapitulates lung barrier function, mucus production, and inflammatory responses.
Advantages
- Air-liquid interface with mechanical breathing captures inhalation-relevant drug exposure
- Human cells enable species-relevant pulmonary pharmacology and toxicology
- Validated for viral infection modeling (SARS-CoV-2, influenza) with immune cell recruitment
- Captures mucociliary clearance and barrier function not possible in static cultures
- Demonstrated utility for inhaled drug formulation development and pulmonary PK
Limitations
- Complex setup — requires specialized equipment and training
- Limited throughput (12-48 chips per run)
- Does not capture full respiratory tract anatomy (trachea to alveoli transitions)
- Mechanical breathing motion systems add cost and complexity
- Regulatory qualification still in progress — not yet a replacement for inhalation toxicology studies
Regulatory Notes
FDA recognizes Lung-Chip as a promising NAM for pulmonary safety and efficacy under the FDA NAMs Roadmap (April 2025). Data has been submitted in IND supplements. EMA has reviewed Lung-Chip data through the Innovation Task Force. Not yet qualified as a replacement for standard 28-day inhalation toxicology studies in rat, but can supplement the safety database and provide human-relevant mechanistic data.
IND Sections Supported
New Approach Methodology (NAM) Context
Can supplement inhalation toxicology animal studies under FDA Modernization Act 2.0. Most commonly used to provide human-relevant data on inhaled formulations or to investigate pulmonary safety signals observed in animal studies. Not yet qualified as a replacement for required in vivo inhalation studies.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Emulate · AlveoliX · Mimetas
Multi-Organ / Body-on-Chip
Multi-organ toxicity and drug-drug interaction assessment, first-pass metabolism effects on systemic exposure, and modeling complex ADME where single-organ systems are insufficient.
Description
Linked microphysiological systems connecting two or more organ models (e.g., liver + kidney, gut + liver + kidney, tumor + liver + immune) through a shared microfluidic circuit to model multi-organ pharmacology, toxicity, and ADME.
Advantages
- Captures inter-organ crosstalk (e.g., liver metabolite causing kidney toxicity)
- Models first-pass metabolism effects on drug exposure at the target organ
- Potential to provide in vitro PK profiles that are more predictive than single-organ data
- Enables modeling of prodrug activation and active metabolite distribution
- Represents the most ambitious and comprehensive NAM platform concept
Limitations
- Most technologically complex and least standardized organ-on-chip platform
- Scaling and media compatibility between organ compartments is a major technical challenge
- Very low throughput — typically 1-6 systems per experiment
- Limited published validation data compared to single-organ platforms
- Common media formulation may not be optimal for all cell types simultaneously
Regulatory Notes
Multi-organ MPS is the least mature organ-on-chip platform from a regulatory perspective. FDA acknowledges the concept through the NAMs Roadmap but has not established qualification criteria or accepted multi-organ MPS data for regulatory decision-making. The technology is in research and development phase. EMA Innovation Task Force has engaged with multi-organ MPS developers but similarly views it as pre-qualification.
IND Sections Supported
New Approach Methodology (NAM) Context
Long-term aspiration to replace certain multi-organ toxicology endpoints, but currently a research tool. Not ready for regulatory submission as primary evidence. May supplement IND submissions with mechanistic data.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Emulate · TissUse (HumiMIC) · CN Bio Innovations
Langendorff Isolated Perfused Heart
Direct cardiac effect assessment of drug candidates on contractility, heart rate, rhythm, and coronary flow without systemic confounders, and proarrhythmic risk evaluation complementary to hERG and in vivo telemetry.
Description
Ex vivo heart preparation perfused retrograde through the aorta with oxygenated Krebs-Henseleit buffer, maintaining spontaneous beating and contractile function for 1-4 hours. Enables direct assessment of cardiac contractility (left ventricular developed pressure), heart rate, coronary flow, ECG parameters (QT interval, rhythm), and arrhythmia susceptibility. First described by Oscar Langendorff in 1895, it remains a cornerstone of cardiac pharmacology and safety assessment.
Advantages
- Isolated heart eliminates neuronal, hormonal, and hemodynamic confounders present in vivo
- Direct measurement of cardiac contractility, coronary flow, and electrophysiology in real time
- Multiple species available — rabbit heart size provides optimal balance of human relevance and practicality
- Enables controlled ischemia-reperfusion injury models and arrhythmia induction protocols
- Cost-effective cardiac safety screening compared to in vivo cardiovascular telemetry studies
Limitations
- Short viability window (1-4 hours) limits to acute drug exposure assessments
- Denervated preparation — cannot assess autonomic nervous system interactions with cardiac effects
- Buffer perfusion rather than blood — may alter drug protein binding and oxygen-carrying capacity
- Technical expertise required for consistent cannulation and quality preparation
- Does not capture systemic PK, metabolite effects, or multi-organ interactions
Regulatory Notes
Langendorff isolated heart preparations are accepted by FDA and EMA as a component of the ICH S7A/S7B cardiovascular safety pharmacology assessment. While not a standalone replacement for in vivo cardiovascular telemetry, Langendorff data provides mechanistic cardiac safety information that supports the overall cardiac risk assessment. The ICH S7B/E14 Q&A (2022) framework recognizes ex vivo cardiac preparations as contributing data for integrated proarrhythmia risk evaluation.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
CorDynamics · Physiostim · Charles River Laboratories
Perfused Organ Systems (ex vivo Perfusion)
Organ-level PK and toxicity assessment with full physiological context, transplantation research, and bridging mechanistic studies between in vitro and in vivo.
Description
Whole organs (typically liver, kidney, heart, or lung) maintained on ex vivo perfusion circuits with oxygenated media or blood products. Preserves complete organ physiology including vascular architecture, innervation remnants, and multi-cell-type interactions.
Advantages
- Complete organ-level physiology with intact vasculature and architecture
- Enables real-time measurement of organ function (bile production, urine output, contractility)
- Human organ perfusion provides the highest level of human relevance short of clinical study
- Well-suited for gene therapy vector transduction efficiency assessment at the organ level
- Can use discarded donor organs, reducing waste while generating valuable data
Limitations
- Extremely limited tissue supply — depends on donor organs not suitable for transplant
- Short viability window (4-24 hours for most organs)
- Technically demanding — requires perfusion equipment, expertise, and immediate processing
- Very low throughput (typically 1-3 organs per experiment)
- Cost per experiment is very high due to organ procurement and perfusion infrastructure
Regulatory Notes
Ex vivo perfused organ data has been accepted in IND submissions as supplementary mechanistic evidence, particularly for gene therapy programs demonstrating organ-level transduction. FDA views this as valuable supporting data but not a standard or required element of the nonclinical package. The technology is more commonly used in academic research than in regulatory submissions.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
OrganOx (liver) · XVIVO Perfusion (lung) · Academic centers (Mayo, MGH, Penn)
Precision-Cut Tissue Slices (Liver, Lung)
Human-relevant organ-level toxicity assessment with intact tissue architecture, fibrosis modeling, and bridging between in vitro and in vivo toxicology data.
Description
Thin (200-300 micron) slices of intact tissue (liver, lung, kidney, intestine) maintaining native architecture, cell-cell contacts, and extracellular matrix. Prepared from human surgical resections, donor organs, or animal tissue. Cultured in submerged or air-liquid interface conditions.
Advantages
- Preserves native tissue architecture, cell-type composition, and extracellular matrix
- All cell types present in physiological ratios — hepatocytes, stellate, Kupffer, endothelial in liver
- Human tissue slices provide direct human relevance without species translation
- Established method for fibrosis and steatosis modeling in liver and lung
- Enables assessment of tissue-level responses not captured by cell culture
Limitations
- Limited viability (24-96 hours for most tissues) restricts chronic exposure studies
- Human tissue availability dependent on surgical schedules and donor organs
- Standardization is challenging — variability between donors and tissue regions
- Slice thickness and orientation affect reproducibility
- Requires rapid processing of fresh tissue — logistically demanding
Regulatory Notes
FDA recognizes PCTS as a scientifically valid system for supplementary toxicology data. Human liver slices are accepted for CYP induction assessment as an alternative to hepatocyte cultures per the 2020 FDA Drug Interaction Guidance. PCTS data has been included in INDs as supporting mechanistic toxicology evidence. The intact tissue architecture provides data quality that FDA reviewers value for understanding organ-level drug effects.
IND Sections Supported
New Approach Methodology (NAM) Context
Human PCTS can reduce the need for certain animal toxicology screens under FDA Modernization Act 2.0 by providing human-relevant organ-level toxicity data. Most commonly used to bridge between in vitro findings and animal study results, or to assess human relevance of animal toxicology signals.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
REPROCELL (Biopta) · Zyagen · BioIVT
Skin Explant Models
Dermal drug absorption and permeation studies, skin irritation/corrosion testing, wound healing evaluation, and topical formulation development.
Description
Full-thickness or split-thickness human skin maintained in culture for dermal drug penetration, irritation, sensitization, and wound healing studies. Obtained from surgical waste (abdominoplasty, breast reduction) or cadaveric donors.
Advantages
- Full-thickness human skin with intact stratum corneum, dermis, and appendages
- Gold standard for dermal permeation and Franz cell diffusion studies
- OECD-validated for skin corrosion (TG 431) and irritation (TG 439) testing
- Avoids animal testing for dermal safety — well-established NAM with regulatory acceptance
- Widely available from surgical waste and commercial tissue banks
Limitations
- Donor variability (age, body site, health status) affects permeation characteristics
- Limited viability (48-72 hours for most applications)
- Does not capture systemic absorption or immune cell trafficking
- Metabolic activity decreases over time in culture
- Availability can be intermittent depending on surgical schedules
Regulatory Notes
Human skin explant/reconstructed skin models are OECD-validated and accepted by FDA and EMA for skin corrosion (OECD TG 431), skin irritation (OECD TG 439), and skin sensitization Defined Approach (OECD GL 497). Franz cell permeation studies on human skin are the gold standard for topical drug PK and are required for ANDA topical product submissions. This is an established regulatory method, not an emerging NAM.
IND Sections Supported
New Approach Methodology (NAM) Context
Fully established replacement for animal skin testing. OECD-validated methods replace Draize rabbit skin irritation and guinea pig sensitization tests. EU cosmetics regulations (Regulation 1223/2009) ban animal testing for cosmetics, requiring these human skin alternatives.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Genoskin · REPROCELL (Biopta) · BioIVT
Tumor Explant Cultures
Patient-specific drug sensitivity testing with preserved tumor microenvironment, biomarker validation, and translational pharmacology studies.
Description
Fresh patient tumor tissue maintained in short-term culture (histoculture or organotypic slice culture) preserving original tumor architecture, stromal components, and immune infiltrate. Used for ex vivo drug sensitivity testing with intact tumor microenvironment.
Advantages
- Preserves native tumor microenvironment including immune infiltrate, stroma, and vasculature
- Patient-specific response data can inform precision medicine strategies
- Intact immune contexture enables evaluation of immunotherapy mechanisms ex vivo
- Short turnaround (48-96 hours) compared to PDX or organoid establishment
- Bridges the gap between in vitro and in vivo oncology models
Limitations
- Short viability window (48-120 hours) limits to acute drug exposure studies
- Tissue quality highly dependent on surgical procurement and transport logistics
- High variability between samples — requires sufficient biological replicates
- No standardized readout or scoring system across the field
- Cannot assess systemic PK, chronic exposure, or metastasis
Regulatory Notes
Tumor explant data is accepted as supportive evidence in IND pharmacology sections but is not a required or qualified method. FDA views this as valuable translational data that can strengthen the clinical development rationale, especially for patient selection strategies. Most commonly cited in Module 2.6.2 scientific rationale.
IND Sections Supported
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Champions Oncology · Oncotest (Charles River) · Nilogen Oncosystems
AI/ML Predictive Models
Large-scale compound screening and prioritization, toxicity prediction across multiple endpoints, clinical trial outcome prediction, and augmenting decision-making at portfolio level.
Description
Machine learning and deep learning models trained on large preclinical and clinical datasets to predict drug properties, toxicity, efficacy, and clinical outcomes. Includes ADME prediction, clinical trial success probability, target identification, and adverse event prediction.
Advantages
- Can screen millions of compounds in hours for multiple ADME and toxicity endpoints
- Continuously improving as training datasets grow and model architectures advance
- Some models (e.g., ADME prediction) now rival experimental assay accuracy for common endpoints
- Enables identification of non-obvious structure-toxicity relationships through deep learning
- FDA has signaled increasing openness to AI/ML-supported regulatory submissions
Limitations
- Model performance is limited by training data quality, diversity, and size
- Black-box nature of deep learning models raises regulatory interpretability concerns
- Prospective validation against experimental data is essential but often lacking
- Applicability domain is difficult to define — may produce confident but incorrect predictions outside training space
- No standardized regulatory framework for evaluating AI/ML model credibility in drug development
Regulatory Notes
FDA published a Discussion Paper on AI/ML in Drug Development (2023) and the CDER AI/ML Framework (2024) outlining expectations for model transparency, validation, and documentation. FDA has accepted AI/ML predictions as supporting data in IND submissions but has not established formal qualification criteria. The April 2025 FDA NAMs Roadmap identifies AI/ML as a cross-cutting enabler for NAMs. EMA established an AI reflection paper (2023). Regulatory acceptance is growing but remains case-by-case.
IND Sections Supported
New Approach Methodology (NAM) Context
AI/ML models can optimize study design and reduce animal use by better predicting which compounds should advance to in vivo testing. Not yet accepted as a standalone replacement for any required regulatory study, but increasingly used to prioritize and design nonclinical programs more efficiently. The combination of AI/ML with other NAMs (organ-on-chip, organoids) is an active area of FDA interest.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Recursion Pharmaceuticals · Insilico Medicine · Numerion Labs (formerly Atomwise)
PBPK Modeling (Physiologically Based Pharmacokinetic)
First-in-human PK prediction, clinical DDI risk assessment, pediatric dose extrapolation, organ impairment dosing, and supporting dose selection in the IND.
Description
Computational models integrating drug physicochemical properties, in vitro ADME data, and physiological parameters to predict human PK, tissue distribution, and drug-drug interactions. Widely used for first-in-human dose prediction, pediatric extrapolation, and organ-specific exposure estimation.
Advantages
- Predicts human PK from in vitro data before any human dosing
- FDA and EMA have specific PBPK guidance and routinely accept PBPK analyses
- Can replace clinical DDI studies when appropriately validated per FDA DDI Guidance (2020)
- Enables dose adjustment predictions for pediatric, hepatic/renal impairment, and genetic polymorphisms
- Integrates all available data (in vitro, preclinical, clinical) into a unified quantitative framework
Limitations
- Model quality depends on accuracy of input parameters (in vitro ADME, physicochemical properties)
- Complex biologics (mAbs, gene therapies) have less mature PBPK frameworks than small molecules
- Requires specialized software (Simcyp, GastroPlus, PK-Sim) and pharmacometric expertise
- Model verification against observed clinical data is needed for regulatory confidence
- Cannot predict novel toxicity or efficacy — only PK-related endpoints
Regulatory Notes
FDA published dedicated PBPK guidance in 2018 (Physiologically Based Pharmacokinetic Analyses — Format and Content) and expanded guidance in the 2020 Drug Interaction Guidance. FDA has accepted PBPK analyses to waive clinical DDI studies in multiple NDA/BLA submissions. EMA published PBPK qualification guidelines in 2018. PBPK-based pediatric extrapolation is accepted per FDA and EMA pediatric guidance. This is one of the most mature and widely accepted in silico approaches in drug development.
IND Sections Supported
New Approach Methodology (NAM) Context
PBPK modeling can reduce the need for some in vivo PK studies by predicting human-relevant PK from in vitro data. Under FDA guidance, a verified PBPK model can replace clinical DDI studies — one of the most mature examples of an in silico NAM reducing both animal and clinical studies.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Certara (Simcyp) · Simulations Plus (GastroPlus) · Open Systems Pharmacology (PK-Sim, open source)
QSAR / In Silico Toxicology
Mutagenicity assessment of impurities (ICH M7 requirement), early toxicity hazard identification, structure-activity screening of compound libraries, and regulatory-compliant impurity qualification.
Description
Computational models (QSAR, read-across, structural alerts, expert rule systems) that predict toxicity endpoints from chemical structure. Used for genotoxicity, carcinogenicity, skin sensitization, hepatotoxicity, and environmental toxicity prediction. Includes Ames/mutagenicity QSAR per ICH M7.
Advantages
- ICH M7 mandates QSAR mutagenicity assessment for drug impurities — established regulatory requirement
- Rapid and inexpensive — can screen thousands of compounds in hours
- Reduces the number of in vitro and in vivo genotoxicity studies needed
- Structural alert databases (Derek Nexus, ToxTree) are well-validated and widely accepted
- Supports read-across approaches for toxicity prediction per OECD Toolbox
Limitations
- Limited to chemical space represented in training data — novel scaffolds may fall outside domain
- Cannot predict mechanism-based or idiosyncratic toxicity from structure alone
- ICH M7 requires complementary (rule-based + statistical) QSAR approaches
- False positive rates for some endpoints can be high, triggering unnecessary follow-up testing
- Not applicable to biologics, gene therapies, or cell therapies
Regulatory Notes
ICH M7(R2) requires (Q)SAR mutagenicity assessment for drug impurities using two complementary methodologies (expert rule-based and statistical). FDA, EMA, and PMDA all require ICH M7-compliant QSAR analysis in IND/NDA/MAA submissions. OECD QSAR Toolbox is accepted for read-across and category approach assessments. Derek Nexus (Lhasa) and CASE Ultra (Leadscope/Instem) are the most widely used regulatory-grade QSAR platforms.
IND Sections Supported
New Approach Methodology (NAM) Context
ICH M7 QSAR analysis directly replaces in vitro Ames testing for impurity mutagenicity assessment — one of the most established in silico NAMs in regulatory use. A negative QSAR assessment (using two complementary approaches) is sufficient to classify an impurity as non-mutagenic without any in vitro or in vivo follow-up testing.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Lhasa Limited (Derek Nexus, Zeneth) · Instem (Leadscope) · Schrodinger (QikProp)
QSP Modeling (Quantitative Systems Pharmacology)
Clinical dose-response prediction, combination therapy optimization, virtual clinical trial simulation, and supporting clinical development strategy decisions.
Description
Mechanistic mathematical models incorporating disease biology, drug pharmacology, and patient physiology to simulate therapeutic outcomes. Used for dose-response prediction, combination therapy optimization, biomarker identification, and virtual patient simulations.
Advantages
- Integrates disease biology and drug pharmacology to predict clinical efficacy and safety
- Virtual patient populations enable simulation of clinical trial outcomes before dosing patients
- Supports rational combination therapy design by modeling synergy and antagonism mechanistically
- Can identify predictive biomarkers and responder populations computationally
- Growing FDA acceptance — over 150 QSP-supported submissions reviewed through 2020, continuing to grow
Limitations
- Model complexity requires extensive parameterization and validation against clinical data
- High-quality models take 6-12+ months to develop and require deep disease biology expertise
- Model predictions are only as good as the biological knowledge and data used for calibration
- No standardized approach for QSP model qualification across regulatory agencies
- Requires specialized computational pharmacology expertise not commonly available in small biotechs
Regulatory Notes
FDA Model-Informed Drug Development (MIDD) Pilot Program (2018-present) has reviewed and accepted QSP models for dose selection, patient stratification, and clinical trial design. FDA published a discussion paper on QSP regulatory applications in 2024. QSP models have been used to support dose selection in multiple IND submissions, particularly in immuno-oncology. EMA published a draft reflection paper on model-informed drug development in 2023. Not yet a required element but increasingly valued for complex dose-response questions.
IND Sections Supported
New Approach Methodology (NAM) Context
QSP models can optimize nonclinical study design and reduce the number of in vivo studies needed by predicting which doses and combinations are most likely to translate clinically. Not a direct replacement for animal studies but can reduce the scope and number of studies required.
Study Types
Modalities
Therapeutic Areas
Development Stages
Key Providers
Rosa & Co. · Certara (QSP division) · Applied BioMath
This tool provides general directional guidance for educational purposes. Model selection should be tailored to your specific program through regulatory consultation and, where appropriate, Pre-IND meeting interactions with FDA. Cost estimates are illustrative ranges based on industry benchmarks, not quotes. Regulatory guidance evolves; confirm current requirements before committing resources. For a program-specific preclinical strategy, book a Strategy Call.
The BridgeLine Brief
Strategy breakdowns, deal analysis, and drug development insights you won't find anywhere else. Written from inside the industry by someone who has built programs and evaluated companies firsthand. Plus updates when we publish new guides, tools, and resources for early-stage biotech teams.
By subscribing you agree to our Privacy Policy.
Need a Program-Specific Model Strategy?
The Navigator shows you the landscape. BridgeLine builds you the plan. Book a complimentary Strategy Call to discuss your program's modality, indication, and development stage, and get a tailored recommendation.
Book a Strategy CallComplimentary · 30 minutes · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com